Canine Geroscience — Structured Evidence Appendix

Purpose. This appendix is an evidence map linking each biological system, scored pathway, and ingredient in the canine geroscience framework to its primary literature. It is not a sales document. Every claim is graded (A/B/C/D), every pharmacokinetic assumption is tagged (PK1/PK2/PK3), and every gap is stated explicitly. Where canine data are absent, the document says so.

How to read this document. Each node follows the same four-section template: Biological role (what the system or compound does and why it matters for canine aging), Claims supported (specific assertions the literature can defend), Where this fits (cross-references to other nodes and site architecture), and Primary literature (full citations with PubMed/DOI links preserved). Nodes are organized into five tiers: Framework Foundations (Tier A), Control Systems (Tier B), BDC Subsystems (Tier C), Ingredients (Tier D), and Cross-Cutting Topics (Tier E).

Evidence grading key. A = canine RCT or controlled interventional trial. B = canine longitudinal/observational cohort. C = rodent interventional with translational plausibility. D = mechanistic, in vitro, human clinical, or theoretical. PK1 = canine oral pharmacokinetics demonstrated. PK2 = plausible but form-dependent or extrapolated. PK3 = unknown or highly uncertain in dogs.

---

Tier A — Framework Foundations

---

N01 — Tier-1 Levers (Body Condition, Exercise, EPA/DHA, Veterinary Screening, Dental Care)

Biological role. Tier-1 levers represent the highest-confidence, highest-impact interventions for canine longevity. Caloric restriction to maintain lean body condition (BCS 4–5/9) is the only intervention proven to extend median lifespan in a controlled canine trial (+1.8 years; Kealy et al. 2002). Exercise activates AMPK, promotes autophagy, and triggers hormetic Nrf2 upregulation at zero cost. EPA/DHA supplementation (50–100 mg/kg/day) is the only nutritional input with Grade A evidence across multiple aging systems. Regular veterinary screening with SDMA-based panels detects subclinical organ reserve depletion before clinical disease manifests. Periodontal disease, present in up to 80% of dogs, is simultaneously the most common and most undertreated source of chronic systemic inflammation.

Claims supported.

• Lean body condition is the single strongest longevity lever in dogs; 25% caloric restriction extended median lifespan by 1.8 years in 48 Labrador Retrievers [A]
• More than 50% of US dogs are estimated overweight or obese, creating a persistent execution gap between known science and owner practice
• EPA/DHA at therapeutic doses (50–100 mg/kg/day) have Grade A evidence for benefit in osteoarthritis, dermatitis, cardiac, and renal domains
• Dental disease drives oral-systemic inflammation with demonstrated cardiac, hepatic, and renal consequences
• Supplemental interventions are adjunctive to, and do not replace, Tier-1 levers
• SDMA-based screening detects chronic kidney disease earlier than creatinine alone

Where this fits.

• → Parent framework: Canine Geroscience Overview
• → Downstream: all six control systems (N03–N08) are modulated by Tier-1 levers
• → Ingredient crossover: EPA/DHA (N26) is the nutritional Tier-1 lever
• → Site architecture: /evidence/tier-1-levers, /blog/body-condition-longevity
• → Regulatory: Boundary Statements (N38) — nutrition supports normal structure/function

Primary literature.

1. Kealy RD et al. (2002). Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc, 220(9):1315-1320. PubMed · DOI — Landmark 48-Labrador paired-feeding RCT: 25% caloric restriction → +1.8 yr median lifespan. [A]
2. Lawler DF et al. (2008). Diet restriction and ageing in the dog: major observations over two decades. Br J Nutr, 99(4):793-805. PubMed · DOI — Two-decade synthesis of Kealy CR study with expanded metabolic biomarkers.
3. Creevy KE et al. (2022). An open science study of ageing in companion dogs. Nature, 602:51-57. PubMed · DOI — Dog Aging Project foundational paper; largest longitudinal companion-animal study.
4. Kaeberlein M, Creevy KE, Promislow DEL (2016). The Dog Aging Project: Translational Geroscience in Companion Animals. Mamm Genome, 27:279-288. PubMed · DOI — Rationale for companion dogs as translational geroscience models.
5. Bauer JE (2011). Therapeutic use of fish oils in companion animals. J Am Vet Med Assoc, 239(11):1441-1451. PubMed · DOI — Comprehensive EPA/DHA dosing review for canine conditions.
6. Magalhães TR et al. (2021). Therapeutic Effect of EPA/DHA Supplementation in Companion Animal Diseases: A Systematic Review. In Vivo, 35(3):1419-1436. PMC — 23-study systematic review confirming omega-3 benefit in OA, dermatitis, cardiac.
7. Mehler SJ et al. (2016). Double-blind, placebo-controlled RCT of EPA/DHA in canine OA. Prostaglandins Leukot Essent Fatty Acids. PubMed · DOI — 78 dogs; significant improvement at 69 mg/kg/day.
8. APOP (2022). U.S. Pet Obesity Prevalence Survey. — 59% of US dogs overweight/obese.
9. Marshall WG et al. (2020). Frequency and impact of periodontal disease in dogs. J Small Anim Pract. PubMed · DOI — PD prevalence up to 80%; systemic inflammation consequences.
10. Fernandes NA et al. (2019). Relation between periodontal disease and systemic diseases in dogs. Res Vet Sci. — Oral-systemic inflammation axis: cardiac, hepatic, renal links.
11. Vendramini THA et al. (2025). Efficacy and optimal dosages of omega-3 for companion animals. Nutr Res Rev. PubMed · DOI — Optimal dosing: OA 48-100 mg/kg EPA, cardiology 27-54 mg/kg EPA.

---

N02 — Evidence Grading & PK Methodology (A/B/C/D Grades, Downgrade Factors, PK1/2/3 Tags)

Biological role. This node defines the epistemic framework used throughout the canine geroscience corpus. Evidence is stratified into four tiers: Grade A (canine RCT with direct species-specific causal inference), Grade B (canine longitudinal cohort providing association data), Grade C (rodent interventional with conserved but uncertain translational plausibility), and Grade D (mechanistic, in vitro, or human clinical data at hypothesis-grade). PK confidence tags (PK1/PK2/PK3) independently assess whether oral bioavailability has been demonstrated in dogs, recognizing that canine gastrointestinal physiology differs significantly from humans. Evidence ceiling weighting (A=1.0×, B=0.85×, C=0.65×, D=0.50×) and PK modifiers (PK1=1.0×, PK2=0.90×, PK3=0.75×) quantitatively discount claims that lack direct canine validation.

Claims supported.

• Grade A = controlled canine RCT; Grade B = canine observational; Grade C = rodent translational; Grade D = mechanistic/in vitro
• Downgrade factors include: small N (<20), surrogate endpoints, lack of blinding, absence of canine PK, short duration (<8 weeks), dose mismatch
• PK1 = canine oral PK demonstrated; PK2 = plausible but extrapolated; PK3 = unknown in dogs
• Human-canine oral bioavailability cannot be predicted from BCS/BDDCS classification systems (Papich & Martinez 2019)
• Manufacturer-funded studies without independent replication are noted with appropriate skepticism

Where this fits.

• → Applied across: all Tier B (N03–N08), Tier C (N09–N14), and Tier D (N15–N35) nodes
• → Scoring engine: BDC Scoring Methodology (N36)
• → Regulatory framing: Boundary Statements (N38)
• → Site architecture: /evidence/methodology, /about/evidence-standards

Primary literature.

1. López-Otín C et al. (2013). The Hallmarks of Aging. Cell, 153(6):1194-1217. PubMed · DOI — Original 9-hallmark framework; foundation for six control systems. [Foundational]
2. López-Otín C et al. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2):243-278. PubMed · DOI — Updated to 12 hallmarks; adds macroautophagy, chronic inflammation, dysbiosis.
3. Kennedy BK et al. (2014). Geroscience: linking aging to chronic disease. Cell, 159(4):709-713. PubMed · DOI — Seven pillars of geroscience; multi-pathway evidence framework.
4. Franceschi C et al. (2018). Inflammaging: a new immune-metabolic viewpoint. Nat Rev Endocrinol, 14(10):576-590. — Defines inflammaging concept underpinning control system evidence grading.
5. Papich MG, Martinez MN (2019). Reconciling Human-Canine Differences in Oral Bioavailability. AAPS J. PubMed · DOI — Demonstrates why PK1/2/3 tags are necessary; BCS/BDDCS cannot predict canine bioavailability from human data.
6. Aragón-Vela J et al. (2022). Systematic Review of Diets and Nutraceuticals in Canine/Feline OA. Int J Mol Sci, 23(18):10384. PubMed · DOI — 57-article review demonstrating quality variation in veterinary nutraceutical evidence.
7. Vandeweerd JM et al. (2012). Systematic review of nutraceutical efficacy for OA. J Vet Intern Med. PubMed · DOI — Evidence poor for all nutraceuticals except omega-3 in dogs.
8. Dean RS et al. (2024). Evidence-based veterinary medicine — potential, practice, and pitfalls. Vet Rec. PMC — GRADE, RoB2, study quality tools for veterinary evidence grading.
9. de Abreu RC et al. (2024). Hallmarks of aging as conceptual framework. Front Aging. PMC — Hallmark validation criteria and hierarchical evidence classification.
10. Boothe DM (2021). Veterinary Pet Supplements and Nutraceuticals. Vet Clin North Am. PMC — Regulatory gaps, PK unknowns, quality control for veterinary supplements.

---

Tier B — Six Control Systems

---

N03 — System 1: Nutrient-Sensing & Metabolic Regulation (mTOR, AMPK, Insulin/IGF-1, Sirtuins)

Biological role. The nutrient-sensing network — mTOR, AMPK, insulin/IGF-1, and sirtuins — integrates amino acid, growth factor, and energy signals to balance cellular growth against repair. Chronic mTOR activation suppresses autophagy and accelerates cellular aging; AMPK, the opposing energy sensor, declines in responsiveness with age. In dogs, the IGF-1 axis is among the most robust geroscience associations: smaller breeds with lower IGF-1 (driven by the IGF1 gene variant) live significantly longer than large breeds. Sirtuins (SIRT1–7), NAD⁺-dependent deacetylases, lose activity as NAD⁺ levels fall with age. Caloric restriction, the only intervention proven to extend canine lifespan, operates primarily through this system by suppressing mTOR and activating AMPK.

Claims supported.

• mTOR is a kinase complex integrating amino acid, growth factor, and energy signals; chronic activation suppresses autophagy and accelerates aging
• AMPK is the cellular energy sensor activated by low energy states; functionally antagonistic to mTOR; responsiveness declines with age
• Small dogs (lower IGF-1) live longer than large dogs — one of the most robust canine geroscience associations
• Sirtuins are NAD⁺-dependent deacetylases; activity declines with age as NAD⁺ falls
• Kealy et al. (2002) caloric restriction: +1.8 yr median lifespan in lean-fed Labradors [A]
• Metabolic health is the upstream master regulator; body condition is the single most actionable longevity lever

Where this fits.

• → BDC Subsystem: Nutrient Sensing & Autophagy (N12)
• → Ingredients acting on this system: NR/NMN (N15), B-Vitamins (N16), Quercetin (N22), Resveratrol (N28), EPA/DHA (N26)
• → Cross-system cascade: mTOR overactivation → NF-kB → inflammaging (N04)
• → Tier-1 Levers (N01): body condition and CR operate through this system
• → Site architecture: /evidence/system-1-nutrient-sensing

Primary literature.

1. Urfer SR et al. (2017). Rapamycin RCT in 24 middle-aged companion dogs. GeroScience, 39(2):117-127. PubMed · DOI — First canine rapamycin RCT; improved cardiac function, no side effects. [A]
2. Dog Aging Project Consortium (2025). TRIAD study design and rationale. GeroScience. PMC — 580-dog multi-site RCT with lifespan as primary endpoint.
3. Greer KA et al. (2007). Effects of height and weight on life span of the domestic dog. Res Vet Sci, 82(2):208-214. — Body weight stronger lifespan predictor than height or breed.
4. Greer KA et al. (2011). Connecting serum IGF-1, body size, and age in the domestic dog. Age (Dordr), 33(3):475-483. PubMed · DOI — Larger breeds = higher IGF-1 = shorter lifespan.
5. Harrison DE et al. (2009). Rapamycin extends lifespan in genetically heterogeneous mice. Nature, 460:392-395. — Landmark mouse mTOR inhibition lifespan extension. [C translational]
6. Imai S, Guarente L (2014). NAD+ and sirtuins in aging and disease. Trends Cell Biol, 24(8):464-471. PubMed · DOI — NAD+ decline drives sirtuin inactivation with aging.
7. Verdin E (2015). NAD+ in aging, metabolism, and neurodegeneration. Science, 350(6265):1208-1213. — NAD+ as central declining metabolic cofactor.
8. Watowich MM et al. (2024). NAD+ precursor + senolytic improves cognitive function in senior dogs. Sci Rep. Nature — 70-dog RCT; significant cognitive improvement. [A]
9. SIRT6 canine study (2025). SIRT6 gene variants and canine longevity. BMC Genomics. PMC — Breed-specific SIRT6 splicing variants may modulate IGF-1 pathway.
10. SIRT1 canine study (2018). SIRT1 protein expression in canine leukocytes. J Vet Med Sci. PMC — First detection of SIRT1 in dog blood cells.
11. Kealy RD et al. (2002). Diet restriction and life span in dogs. JAVMA, 220(9):1315-1320. — CR extends lifespan via nutrient-sensing modulation. [A]

---

N04 — System 2: Inflammatory Tone & Immune Aging (Inflammaging, NF-kB, SPMs)

Biological role. Inflammaging — chronic, sterile, low-grade inflammation — is the dominant shared mechanism linking aging to age-related disease in mammals. NF-kB activity increases with age across all tissues, driving IL-1β, IL-6, and TNF-α production. The NLRP3 inflammasome becomes chronically overactive. Simultaneously, immunosenescence produces immune decline (thymic involution, reduced naïve T-cells) alongside inflammatory overactivation. EPA/DHA-derived specialized pro-resolving mediators (resolvins, protectins, maresins) actively terminate inflammation but decline with age. In dogs, the Dog Aging Project pilot demonstrated age-associated increases in IL-6, IL-8, and TNF-α in clinically healthy animals, and periodontal disease — present in up to 80% of dogs — is both a consequence and driver of systemic inflammaging.

Claims supported.

• Inflammaging is the dominant shared mechanism linking aging to chronic disease in mammals
• NF-kB activity increases with age across all tissues; drives IL-1β, IL-6, TNF-α production
• EPA/DHA-derived SPMs (resolvins, protectins, maresins) actively terminate inflammation; their synthesis declines with age
• Periodontal disease is both consequence and driver of systemic inflammaging
• EPA/DHA have Grade A evidence for anti-inflammatory effect in dogs across multiple trials
• Chronic low-grade inflammation is detectable via elevated CRP and IL-6 in clinically healthy senior dogs [B]

Where this fits.

• → BDC Subsystem: Inflammaging & Immune Calibration (N11)
• → Ingredients acting on this system: EPA/DHA (N26), Curcumin (N27), Quercetin (N22), Beta Glucans (N23), Reishi (N24), Spirulina (N25)
• → Upstream driver: mTOR overactivation from System 1 (N03) upregulates NF-kB
• → Downstream consequence: chronic inflammation generates ROS → System 3 (N05)
• → Site architecture: /evidence/system-2-inflammation

Primary literature.

1. McKenzie BA (2025). Immunosenescence and Inflammaging in Dogs and Cats. J Vet Intern Med. PMC — Most comprehensive canine inflammaging review to date.
2. Schmid SM et al. (2024). Companion dog as inflammaging model: DAP pilot study. GeroScience. PubMed · DOI — 47 dogs: IL-6, IL-8, TNF-alpha increase with age.
3. Alexander JE et al. (2018). Longitudinal markers of inflammation in 80 Labradors. J Gerontol A, 73(6):720-728. PubMed · DOI — HSP70 declines, IgM and 8-OHdG increase with age.
4. Day MJ (2010). Ageing, immunosenescence and inflammageing in the dog and cat. J Comp Pathol. PubMed · DOI — Early foundational review of canine immune aging.
5. Franceschi C et al. (2018). Inflammaging: immune-metabolic viewpoint. Nat Rev Endocrinol, 14(10):576-590. — Definitive inflammaging framework.
6. Serhan CN (2018). Resolvins: pro-resolving superfamily of mediators. J Clin Invest. JCI — Definitive SPM biology review.
7. Bauer JE (2011). Therapeutic fish oils in companion animals. JAVMA, 239(11):1441-1451. — EPA/DHA anti-inflammatory dosing for dogs. [A]
8. Marshall WG et al. (2020). Periodontal disease frequency and impact in dogs. J Small Anim Pract. — Oral-systemic inflammaging axis.
9. Bosco N, Noti M (2021). Aging gut microbiome and host immunity. Genes Immun. — Gut-immune axis changes with aging.
10. Pilla R, Suchodolski JS (2020). Canine gut microbiome in health and disease. Front Vet Sci. — Canine-specific microbiome, SCFA, immune modulation.

---

N05 — System 3: Oxidative Stress & Cellular Defense (ROS, Nrf2, GSH, Mitophagy)

Biological role. Reactive oxygen species are inevitable mitochondrial respiration byproducts — hormetic at low levels, damaging in excess. Nrf2, the master regulator of antioxidant gene expression via the Keap1/ARE pathway, declines in responsiveness with age. Glutathione (GSH), the most abundant intracellular antioxidant, also declines significantly. A critical nuance: oxidative stress is more often a downstream consequence of metabolic dysregulation and inflammation than a primary cause of aging. High-dose single-antioxidant supplementation trials have largely failed to extend lifespan in rodents. Supporting endogenous antioxidant systems (Nrf2 induction, GSH synthesis substrates) is more effective than exogenous antioxidant flooding. Exercise remains the most potent known Nrf2 activator.

Claims supported.

• Nrf2 is the master regulator of antioxidant gene expression; responsiveness declines with age
• GSH is the most abundant intracellular antioxidant; levels decline significantly with age
• Oxidative stress is more often a downstream consequence of metabolic dysregulation than a primary cause of aging
• High-dose single-antioxidant supplementation trials have largely failed to extend lifespan in rodents [C]
• Supporting endogenous antioxidant systems (Nrf2, GSH synthesis) is more effective than exogenous antioxidant flooding
• Enzymatic antioxidants (SOD, catalase, GPx) require mineral cofactors: Zn, Cu, Mn, Se

Where this fits.

• → BDC Subsystems: Oxidative Defense & Redox Balance (N10), Mitochondrial Integrity (N09)
• → Ingredients acting on this system: Glutathione/NAC (N17), Astaxanthin (N19), Vitamins C & E (N20), CoQ10 (N18), Blueberry (N21)
• → Upstream driver: inflammaging from System 2 (N04) generates ROS
• → Downstream consequence: persistent oxidative DNA damage triggers senescence → System 4 (N06)
• → Site architecture: /evidence/system-3-oxidative-defense

Primary literature.

1. Ma Q (2013). Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. PubMed · DOI — Nrf2/Keap1/ARE pathway as master antioxidant regulator.
2. Surai PF et al. (2024). Dietary antioxidants and free radical damage in dogs/cats. J Anim Sci. PMC — 40 dogs; vitamin E/C/beta-carotene blend reduced oxidation and cellular damage.
3. Cotman CW et al. (2002). Brain aging in the canine: antioxidant diet reduces cognitive dysfunction. Neurobiol Aging. — Aged beagles: antioxidant-enriched diet improved cognition, reduced beta-amyloid.
4. Head E (2009). Antioxidants in the Canine Model of Human Aging. Biochim Biophys Acta. PMC — Canine brain as human aging model; antioxidant diet increased glutathione.
5. Hagen A et al. (2019). Antioxidant supplementation in ill dogs. J Small Anim Pract. PubMed · DOI — 40 dogs; NAC/SAMe/silybin/vit E; only vit E significantly increased.
6. Muršec et al. (2025). Antioxidant Strategies for Age-Related Damage in Dogs. Vet Sci. PMC — Comprehensive 2025 review; notes small samples and biomarker-only outcomes.
7. Sechi et al. (2017). Oxidative stress in therapy dogs: antioxidant supplementation. BMC Vet Res. PMC — 11 dogs crossover RCT; reduced d-ROMs and triglycerides.
8. Alexander JE et al. (2018). Longitudinal oxidative markers in 80 Labradors. J Gerontol A. PubMed — 8-OHdG (DNA oxidation) increases with age in dogs.
9. Various reviews (2014+). Free radical theory reframing. — High-dose single antioxidants failed to extend rodent lifespan.

---

N06 — System 4: Cellular Senescence & Tissue Renewal (SASP, Senolytics, Stem Cells)

Biological role. Senescent cells enter permanent cell-cycle arrest via p16^INK4a/p21 but do not die; they accumulate with age and secrete the senescence-associated secretory phenotype (SASP) — a mixture of pro-inflammatory cytokines, matrix metalloproteinases, and growth factors that damage surrounding tissue. In rodent models, genetic or pharmacologic clearance of senescent cells extends healthspan. Stem-cell exhaustion compounds the problem by reducing tissue renewal capacity. This is the least mature of the six control systems in canine-specific evidence: no senolytic drugs are approved for veterinary use, and the best-studied senolytic combination (dasatinib + quercetin) includes a cancer drug unsuitable for nutraceutical application. Fisetin shows senolytic activity in mice but has no canine PK, dosing, or safety data.

Claims supported.

• Senescent cells accumulate with age and secrete SASP (IL-6, IL-8, MMP3, MMP9, VEGF) damaging surrounding tissue
• In rodent models, genetic or pharmacologic clearance of senescent cells extends healthspan [C]
• No senolytic drugs are approved or standardized for veterinary use in dogs
• Fisetin shows senolytic activity in rodent models but has no canine PK, dosing, or safety data [D]
• This is the least mature of the six control systems in canine-specific evidence
• Stem-cell exhaustion reduces tissue renewal capacity with age

Where this fits.

• → BDC Subsystem: Genomic Stability & Cellular Resilience (N14) — senolytic pathway
• → Ingredients: Fisetin/Spermidine (N29), Quercetin (N22)
• → Upstream driver: persistent oxidative DNA damage from System 3 (N05) triggers senescence
• → Cross-system: SASP drives further inflammation → System 2 (N04) feed-forward loop
• → Site architecture: /evidence/system-4-senescence
• → ⚠️ Weakest canine evidence node — flag for future data acquisition

Primary literature.

1. Williams et al. (2024). Senotherapy potential in veterinary medicine. Front Vet Sci. PubMed · DOI — Comprehensive veterinary senolytic review: pathways, compounds, safety.
2. Watowich MM et al. (2024). Senolytic + NAD+ precursor in senior dogs. Sci Rep. Nature — 70-dog RCT; 88.9% cognitive improvement in full-dose group.
3. Lim et al. (2025). Anti-aging strategies for dogs. J Vet Sci. PMC — Reviews senolytics, rapamycin, stem cells for canine aging.
4. Zhu Y et al. (2015). From transcriptome to senolytic drugs. Aging Cell. — D+Q senolytic combination discovery paper.
5. Xu M et al. (2018). Senolytics improve function and extend lifespan. Nat Med. — D+Q extends lifespan in aged mice.
6. Yousefzadeh MJ et al. (2018). Fisetin as senotherapeutic. EBioMedicine. — Fisetin reduces senescent cells and extends mouse lifespan.
7. Baker DJ et al. (2011). Clearance of p16+ cells delays aging disorders. Nature. — Genetic proof-of-concept for senolytic benefit.

---

N07 — System 5: Genomic & Epigenetic Integrity (DNA Repair, Methylation Clocks, Telomeres)

Biological role. The genome accumulates damage from endogenous sources (ROS, replication errors) and exogenous insults (UV, toxins) over an organism's lifetime, while DNA repair fidelity declines with age. Epigenetic drift — progressive dysregulation of gene expression without DNA sequence changes — is a core hallmark of aging. Canine epigenetic clocks have been developed and validated across 93 breeds by the Dog Aging Project (Thompson et al. 2017; Horvath et al. 2022), making dogs one of the best non-human models for biological age measurement. Telomere attrition correlates with remaining replicative capacity; dogs lose telomeric DNA approximately 10× faster than humans. Genomic integrity is currently more a monitoring domain than a nutritional intervention target — no well-validated nutritional interventions meaningfully alter DNA repair rates or methylation drift in dogs, though folate, B12, and B6 support one-carbon metabolism essential for methylation maintenance.

Claims supported.

• DNA repair fidelity declines with age, tipping balance toward unrepaired damage
• Epigenetic drift is a core hallmark of aging; canine epigenetic clocks validated across 93 breeds [B]
• Dogs lose telomeric DNA ~10× faster than humans; telomere length predicts breed lifespan (p<0.0001)
• No well-validated nutritional interventions meaningfully alter DNA repair rates or methylation drift in dogs
• Folate, B12, B6 support one-carbon metabolism essential for DNA methylation maintenance
• Genomic integrity is currently more a monitoring domain than a nutritional intervention target

Where this fits.

• → BDC Subsystem: Genomic Stability & Cellular Resilience (N14)
• → Ingredients: B-Vitamins (N16), SAMe (N34), EPA/DHA (N26 — telomere protection)
• → Upstream: oxidative DNA damage from System 3 (N05) drives epigenetic drift
• → Dog Aging Project (N40) — epigenetic clock development
• → Site architecture: /evidence/system-5-genomic-integrity

Primary literature.

1. Thompson MJ, vonHoldt B, Horvath S, Pellegrini M (2017). An epigenetic aging clock for dogs and wolves. Aging (Albany NY), 9(3):1055-1068. PubMed · DOI — First canine DNAm clock; 46 dogs, 62 wolves; 41-CpG age estimator with cross-species conservation.
2. Horvath S, Lu AT, Haghani A, et al. (2022). DNA methylation clocks for dogs and humans. Proc Natl Acad Sci USA, 119(21):e2120887119. PubMed · DOI — Mammalian methylation array clocks for 93 dog breeds; dual human-dog clocks (R=0.97).
3. Wang T, Ma J, Hogan AN, et al. (2020). Quantitative Translation of Dog-to-Human Aging by Conserved Remodeling of the DNA Methylome. Cell Syst, 11(2):176-185. PubMed · DOI — 104 Labrador methylomes; nonlinear dog-to-human age translation via conserved developmental gene methylation.
4. Diaz Escarcega ER, et al. (2024). DNA methylation and chromatin accessibility predict age in the domestic dog. Aging Cell. PMC — First dual DNAm + ATAC-seq canine aging clock.
5. Fick LJ, Fick GH, Li Z, et al. (2012). Telomere length correlates with life span of dog breeds. Cell Rep, 2(6):1530-1536. PubMed · DOI — 175 dogs, 26 breeds; PBMC telomere length predicts breed lifespan (p<0.0001); shorter telomeres = higher CVD risk.
6. McKevitt TP, Nasir L, Devlin P, Argyle DJ (2002). Telomere lengths in dogs decrease with increasing donor age. J Nutr, 132(6S):1604S-1606S. PubMed · DOI — Three breeds; age-associated telomere attrition in canine PBMCs.
7. Nasir L, Devlin P, McKevitt T, Rutteman G, Argyle DJ (2001). Telomere lengths and telomerase activity in dog tissues. Neoplasia, 3(4):351-359. PMC — Dogs lose telomeric DNA ~10x faster than humans; no somatic telomerase; superior to rodent models.
8. Park S, Kang S (2023). Modulation of DNA methylation by one-carbon metabolism: a milestone for healthy aging. Nutr Res Pract, 17(4):597-615. PMC — Folate/B12/B6 fuel SAM generation for DNA methylation; age-associated drift modifiable by one-carbon nutrients.
9. Zheng Y, et al. (2020). B Vitamins and One-Carbon Metabolism: Implications in Human Health and Disease. Nutrients, 12(9):2867. PMC — B-vitamin roles in DNA methylation, synthesis, repair; folate deficiency causes uracil misincorporation.
10. Marinelli L, et al. (2025). Telomere Tales: Exploring the Impact of Stress, Sociality, and Exercise on Dogs' Cellular Aging. Vet Sci, 12(5):491. PMC — 2025 review of canine telomere attrition as aging hallmark; stress, exercise, and welfare effects on rTL.

---

N08 — System 6: Organ-System Reserve & Functional Capacity (Renal, Cardiac, Cognitive, MSK)

Biological role. Organ-system reserve is the integrated output of all five preceding control systems. The subclinical gap — the period during which reserve declines for years before clinical disease manifests — is the primary window for nutritional geroscience intervention. In renal aging, 65–75% of nephrons are lost before creatinine rises above reference range. Osteoarthritis is the leading cause of chronic pain and mobility loss in aging dogs and is extremely prevalent after age 7. Canine cognitive dysfunction (CCD) parallels Alzheimer's disease with beta-amyloid deposition; prevalence reaches approximately 28% at age 11–12 and 68% at age 15–16. Myxomatous mitral valve disease (MMVD) affects over 30% of small-breed dogs by age 10. MCT supplementation provides ketone bodies as alternative brain fuel when glucose metabolism becomes impaired.

Claims supported.

• Organ-system reserve declines for years before clinical disease; 65–75% nephron loss occurs before creatinine rises
• OA is the leading cause of chronic pain in aging dogs; extremely prevalent over age 7 [A/B]
• CCD prevalence: ~28% at 11–12 yr, ~68% at 15–16 yr; beta-amyloid parallels Alzheimer's [A/B]
• MCT supplementation provides ketone bodies as alternative brain fuel (Pan et al. 2010) [A]
• MMVD affects >30% of small-breed dogs by age 10 [B/C]
• Sarcopenia is underdiagnosed; muscle condition scoring at every senior visit should be standard

Where this fits.

• → BDC Subsystems: all six (N09–N14) feed into organ-level outcomes
• → Ingredients: MCTs (N31), Taurine (N32), L-Carnitine (N33), CoQ10 (N18), Joint Substrates (N30), EPA/DHA (N26), SAMe (N34)
• → Upstream: all five control systems (N03–N07) converge on organ reserve
• → Cognition-specific: Blueberry (N21), Astaxanthin (N19)
• → Site architecture: /evidence/system-6-organ-reserve

Primary literature.

1. Pan Y, Larson B, Araujo JA, et al. (2010). Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutr, 103(12):1746-1754. PubMed · DOI — Foundational MCT-cognition RCT in aged Beagles; 5.5% MCT diet improved cognition via ketone body mechanism.
2. Dewey CW, Davies ES, Xie H, Wakshlag JJ (2019). Canine Cognitive Dysfunction: Pathophysiology, Diagnosis, and Treatment. Vet Clin North Am Small Anim Pract, 49(3):477-499. PubMed · DOI — CCD prevalence 28% at 11-12 yr, 68% at 15-16 yr; beta-amyloid deposition; treatment approaches.
3. Fast R, Schütt T, Toft N, et al. (2013). Long-Term Follow-Up of Canine Cognitive Dysfunction. J Vet Intern Med, 27:1418-1424. — CCD progression: 33% normal→MCI, 22% MCI→CCD over 2 years.
4. Dog Aging Project (2022). Evaluation of cognitive function: associations with baseline canine characteristics. Sci Rep, 12:13323. Nature — n=15,019; CCD odds +52%/year of age; inactive dogs 6.47x higher risk.
5. Gonzalez Martinez A, et al. (2021). CCD scores correlate with amyloid beta 42 levels in dog brain tissue. J Vet Intern Med. PubMed · DOI — Direct Abeta42-CCD score correlation; sex differences in prefrontal cortex.
6. Keene BW, Atkins CE, Bonagura JD, et al. (2019). ACVIM consensus guidelines for myxomatous mitral valve disease in dogs. J Vet Intern Med, 33(3):1127-1140. PMC — MMVD staging A-D; 75% of canine heart disease; treatment consensus.
7. Mattin MJ, Boswood A, Church DB, et al. (2015). Prevalence of DMVD in dogs in England. J Vet Intern Med, 29(3):847-854. PMC — ~30% of dogs >10 yr; median survival 25.4 months post-diagnosis.
8. Anderson KL, O'Neill DG, Brodbelt DC, et al. (2020). Risk Factors for Canine Osteoarthritis: A Systematic Review. Front Vet Sci, 7:220. PMC — Age and excess weight as primary OA severity contributors.
9. COAST Development Group (2023). International consensus guidelines for the treatment of canine osteoarthritis. Front Vet Sci, 10:1137888. — Multimodal OA management consensus.
10. Pan (2021). Nutrients, Cognitive Function, and Brain Aging: What We Have Learned from Dogs. Med Sci, 9(4):72. PMC — MCT, antioxidants, DHA for canine brain aging; dogs as AD model.

---

Tier C — BDC Subsystems (Biological Defense Coverage)

---

N09 — BDC: Mitochondrial Integrity

Biological role. Mitochondrial dysfunction is a primary driver of cellular energy failure and ROS overproduction in aging. This BDC subsystem models four pathways: ETC cofactor supply, beta-oxidation capacity, membrane composition, and metabolic flexibility. CoQ10 directly supplies the electron transport chain as an electron carrier between Complex I/II and Complex III. L-carnitine directly supplies the beta-oxidation shuttle via carnitine palmitoyltransferase. EPA/DHA remodel cardiolipin — the signature phospholipid of the inner mitochondrial membrane — improving membrane fluidity and ETC coupling efficiency. MCTs (C8/C10) provide ketone bodies as alternative mitochondrial fuel when glucose metabolism is impaired. Dogs have high tetralinoleoyl cardiolipin content, making species-specific membrane composition a relevant consideration.

Claims supported.

• Four pathways modeled: ETC cofactor supply, beta-oxidation capacity, membrane composition, metabolic flexibility
• CoQ10 directly supplies the ETC as Complex I/II→III electron carrier; levels decline with age
• EPA/DHA remodel cardiolipin improving membrane fluidity and ETC coupling efficiency [A]
• MCTs C8/C10 provide ketone bodies as alternative mitochondrial fuel [A]
• L-carnitine directly supplies the beta-oxidation shuttle via CPT-I/CPT-II
• Taurine stabilizes mitochondrial membranes via osmotic buffering [A]

Where this fits.

• → Parent system: System 3 (N05), System 1 (N03)
• → Ingredients: CoQ10 (N18), L-Carnitine (N33), EPA/DHA (N26), MCTs (N31), Taurine (N32), B-Vitamins (N16)
• → Scoring: BDC Scoring Methodology (N36)
• → Site architecture: /evidence/bdc-mitochondrial-integrity

Primary literature.

1. Head E, et al. (2009). Effects of Age, Dietary and Behavioral Enrichment on Brain Mitochondria in a Canine Model of Human Aging. Exp Neurol. PMC — Aged canine brain mitochondria: increased ROS, reduced NADH respiration; antioxidant diet maintained mito homeostasis.
2. Schulz C, et al. (2011). Coenzyme Q10 and Cognition in Atorvastatin Treated Dogs. Neurosci Lett. PMC — Statin-treated beagles: depleted serum CoQ10; mito cofactor-cognition link.
3. Ikematsu H, et al. (2006). Oral Repeated Dose Toxicity Studies of Coenzyme Q10 in Beagle Dogs. Int J Toxicol. PMC — CoQ10 safety in beagles: no adverse effects.
4. Hernandez-Camacho JD, et al. (2018). Coenzyme Q10 Supplementation in Aging and Disease. Front Physiol, 9:44. — CoQ10 as ETC electron carrier Complex I/II→III; levels decline with age.
5. Pan Y, et al. (2010). MCT cognition-enhancing effects in aged dogs. Br J Nutr. PubMed — MCT → ketone bodies as alternative mito fuel.
6. Julienne CM, et al. (2014). Update on lipids and mitochondrial function: impact of dietary n-3 PUFA. Lipids. PMC — DHA increases cardiolipin, decreases mito permeability transition.
7. Novak F, et al. (2023). EPA stronger than DHA increases mitochondrial membrane potential and cardiolipin. Exp Cell Res. PubMed · DOI — EPA dose-dependently increases MMP and cardiolipin.

---

N10 — BDC: Oxidative Defense & Redox Balance

Biological role. This subsystem models five redox pathways: enzymatic antioxidants (SOD/GPx/catalase), GSH synthesis, lipid-phase protection, Nrf2 endogenous upregulation, and membrane lipid peroxidation resistance. Enzymatic antioxidants require specific metallocofactors — selenium for GPx, zinc and copper for Cu/Zn-SOD, manganese for Mn-SOD. NAC and SAMe provide cysteine and GSH synthesis substrates via the rate-limiting gamma-glutamylcysteine synthetase step. Sulforaphane activates Nrf2, inducing enzymes that are not consumed stoichiometrically and can recycle vitamin E and CoQ10. Astaxanthin functions as both a direct lipid-phase antioxidant and a Nrf2 activator. This subsystem achieves the highest pathway-saturation score due to multi-substrate redundancy across all five pathways.

Claims supported.

• Five pathways modeled: enzymatic antioxidants, GSH synthesis, lipid-phase protection, Nrf2 upregulation, membrane lipid peroxidation resistance
• Complete metalloenzyme antioxidant panel: selenium (GPx), zinc+copper (Cu/Zn-SOD), manganese (Mn-SOD)
• NAC and SAMe provide GSH synthesis substrates via the rate-limiting cysteine step
• Sulforaphane activates Nrf2; Nrf2-induced enzymes recycle vitamin E and CoQ10
• Astaxanthin functions as dual Nrf2 activator and direct lipid-phase antioxidant
• Multi-substrate redundancy across all five pathways yields the highest subsystem score

Where this fits.

• → Parent system: System 3 (N05)
• → Ingredients: Glutathione/NAC (N17), Astaxanthin (N19), Vitamins C & E (N20), CoQ10 (N18)
• → Cross-reference: Mitochondrial Integrity (N09) — shared ROS management
• → Scoring: BDC Scoring Methodology (N36)
• → Site architecture: /evidence/bdc-oxidative-defense

Primary literature.

1. Viviano KR, VanderWielen B (2013). NAC Supplementation in Hospitalized Ill Dogs. J Vet Intern Med. PubMed · DOI — NAC RCT: increased plasma cysteine, maintained RBC GSH; illness depletes canine GSH.
2. Martello et al. (2023). S-Acetyl-Glutathione and Silybin in Dogs with Liver Disease. Vet Sci. PMC — SAG increased erythrocyte GSH; improved liver biochemistry.
3. Surai PF, et al. (2024). Dietary antioxidants and free radical damage in dogs. J Anim Sci. PMC — 40 dogs, vitamin E/C/beta-carotene blend; reduced oxidation markers.
4. Kubo E, et al. (2017). Sulforaphane reactivates Nrf2/ARE/Prdx6 during aging. Sci Rep, 7:14130. — SFN dose-dependently augments Prdx6, catalase, GSTpi via Nrf2.
5. Houghton CA, et al. (2016). Sulforaphane and Nutrigenomic Nrf2 Activators. Oxid Med Cell Longev. PMC — Nrf2-induced enzymes not consumed stoichiometrically; recycle vitamin E/CoQ10.
6. Davinelli S, et al. (2021). Nrf2 as molecular therapeutic target for Astaxanthin. Biomed Pharmacother. — Astaxanthin: dual Nrf2 activator + direct lipid-phase antioxidant.
7. Ma Q (2013). Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. PubMed — Definitive Nrf2/Keap1/ARE pathway review.
8. Hagen A, et al. (2019). Antioxidant supplementation in ill dogs. J Small Anim Pract. PubMed — NAC/SAMe/silybin/vitamin E trial; 40 dogs.

---

N11 — BDC: Inflammaging & Immune Calibration

Biological role. This subsystem models five inflammatory/immune pathways: SPM synthesis, NF-kB modulation, leukotriene balance, immune calibration, and gut-immune axis. EPA/DHA anchor SPM synthesis by providing resolvin E1 (from EPA) and resolvin D1/protectin D1 (from DHA) precursors while competitively displacing arachidonic acid from COX/LOX pathways. Curcumin and quercetin address NF-kB modulation at the transcriptional level. Boswellic acids provide 5-LOX inhibition, modulating leukotriene balance. Prebiotics (scFOS, yeast beta-glucans) modulate the gut-immune axis via SCFA production — senior dogs show reduced butyrate and valeric acid levels compared to younger animals. The gut-immune pathway connects intestinal microbial ecology to systemic inflammatory tone.

Claims supported.

• Five pathways modeled: SPM synthesis, NF-kB modulation, leukotriene balance, immune calibration, gut-immune axis
• EPA/DHA [A] and GLA [A] anchor SPM synthesis and eicosanoid balance
• Curcumin + boswellia RCT demonstrated NF-kB + 5-LOX synergy in canine OA [C]
• Prebiotics modulate gut-immune axis via SCFA production [B]
• Senior dogs show reduced butyrate/valeric acid; age-related fermentation shifts documented
• Boswellia achieved 71% mobility improvement within 2 weeks in canine joint/spinal disease

Where this fits.

• → Parent system: System 2 (N04)
• → Ingredients: EPA/DHA (N26), Curcumin (N27), Quercetin (N22), Beta Glucans (N23), Reishi (N24), Spirulina (N25)
• → Cross-reference: Oxidative Defense (N10) — inflammation and ROS feed-forward
• → Scoring: BDC Scoring Methodology (N36)
• → Site architecture: /evidence/bdc-inflammaging

Primary literature.

1. Serhan CN (2018). Resolvins in inflammation: pro-resolving superfamily. J Clin Invest, 128(7):2657-2669. JCI — SPM biology: resolvins, protectins, maresins from EPA/DHA.
2. Magalhães TR, et al. (2021). EPA/DHA Supplementation in Companion Animal Diseases: Systematic Review. In Vivo. PMC — 23 RCTs; anti-inflammatory via arachidonic acid competition + SPM precursors.
3. Colitti M, et al. (2021). Curcuvet + Boswellic acid in canine OA. PLoS One. PMC — Curcumin + boswellia RCT; NF-kB + 5-LOX synergy.
4. Reichling J, et al. (2004). Boswellia resin in canine joint/spinal disease. Schweiz Arch Tierheilkd. PubMed · DOI — 71% dogs improved mobility within 2 weeks.
5. Chang CS, et al. (2010). GLA inhibits NF-kappaB and AP-1 in LPS-induced macrophages. Inflammation. PubMed · DOI — GLA suppresses NF-kB, iNOS, COX-2.
6. Pilla R, Suchodolski JS (2020). Canine Gut Microbiome and Metabolome. Front Vet Sci. — SCFA/butyrate production; gut-immune modulation.

---

N12 — BDC: Nutrient Sensing & Autophagy

Biological role. This subsystem models four pathways: AMPK activation, mTOR calibration, autophagy induction, and sirtuin/NAD⁺. It is the most directly geroscience-relevant subsystem but achieves the lowest BDC score among the six, reflecting the absence of NR or NMN at doses sufficient to meaningfully engage the sirtuin/NAD⁺ pathway. Caloric restriction is the archetypal activator of this system — Kealy et al. (2002) demonstrated +1.8 years via mTOR suppression and autophagy enhancement. Spermidine is a direct autophagy inducer via EP300 acetyltransferase inhibition, but canine data are absent. The gap between actual and theoretical ceiling score is primarily attributable to the sirtuin/NAD⁺ pathway, where NR/NMN remain insufficiently characterized in canine pharmacokinetics.

Claims supported.

• Four pathways: AMPK activation, mTOR calibration, autophagy induction, sirtuin/NAD⁺
• Sirtuin/NAD⁺ pathway is the primary gap — no NR or NMN at sufficient doses
• Spermidine is the direct autophagy inducer via EP300 acetyltransferase inhibition [C/D]
• Caloric restriction activates this system via mTOR suppression + autophagy enhancement [A]
• Evidence predominantly Grade C/D for key nutrient-sensing compounds
• This is the lowest-scoring subsystem despite being most directly geroscience-relevant

Where this fits.

• → Parent system: System 1 (N03)
• → Ingredients: NR/NMN (N15), Quercetin (N22), Resveratrol (N28), Fisetin/Spermidine (N29), MCTs (N31), EPA/DHA (N26)
• → Cross-reference: Mitochondrial Integrity (N09) — metabolic flexibility pathway
• → Scoring: BDC Scoring Methodology (N36)
• → Site architecture: /evidence/bdc-nutrient-sensing
• → ⚠️ Lowest-scoring subsystem — flag for formulation gap analysis

Primary literature.

1. Kealy RD, et al. (2002). Diet restriction and lifespan in dogs. J Am Vet Med Assoc. PubMed — 48 Labradors, +1.8 yr via mTOR suppression + autophagy enhancement.
2. Urfer SR, et al. (2017). Rapamycin in 24 middle-aged companion dogs. GeroScience. PubMed — mTOR inhibition improved cardiac function.
3. DAP Consortium (2025). TRIAD study design. GeroScience. PMC — 580-dog rapamycin RCT; lifespan primary endpoint.
4. Hofer SJ, et al. (2022). Spermidine-induced autophagy and geroprotection. Nat Aging. Nature — EP300 inhibition; lifespan extension across species.
5. Watowich MM, et al. (2024). NAD+ precursor + senolytic in senior dogs. Sci Rep. Nature — 70-dog RCT; cognitive improvement.
6. Imai S, Guarente L (2014). NAD+ and sirtuins in aging. Trends Cell Biol. PubMed — NAD+ decline → sirtuin inactivation; NR/NMN rationale.
7. Chung et al. (2019). Calorie restriction and autophagy in aging. Nutrients. PMC — CR mimetics; mTOR + AMPK + autophagy links.

---

N13 — BDC: Proteostasis & ECM Maintenance

Biological role. This subsystem models three pathways: ECM structural maintenance, protein quality control, and protein oxidation defense. Undenatured type II collagen (UC-II) provides oral tolerance via Peyer's patch-mediated Treg modulation — an immunological mechanism distinct from direct structural supplementation. UC-II has exceptional canine RCT depth: four controlled trials demonstrating non-inferiority to NSAIDs and superiority to glucosamine by objective ground-force plate measurement. Glucosamine HCl, despite being the most commonly marketed joint nutraceutical, shows no significant benefit in meta-analysis. Protein carbonylation defense depends on GSH availability, linking this subsystem to the oxidative defense pathway. Zinc supports proteasomal protein degradation and recycling.

Claims supported.

• Three pathways modeled: ECM structural maintenance, protein quality control, protein oxidation defense
• UC-II provides oral tolerance mechanism via Peyer's patches → Treg modulation [A/B]
• UC-II has four canine RCTs; non-inferior to NSAID; superior to glucosamine by ground-force plate [A]
• Glucosamine shows no significant benefit in meta-analysis of canine OA trials
• Protein carbonylation defense depends on GSH availability — links to oxidative defense pathway
• Zinc supports proteasomal function; taurine provides protein stabilization [A]

Where this fits.

• → Parent system: System 6 (N08) — musculoskeletal domain
• → Ingredients: Joint Substrates (N30), Glutathione/NAC (N17), Vitamins C & E (N20)
• → Cross-reference: Oxidative Defense (N10) — protein oxidation defense via GSH
• → Scoring: BDC Scoring Methodology (N36)
• → Site architecture: /evidence/bdc-proteostasis

Primary literature.

1. D'Altilio M, et al. (2007). UC-II singly or combined with glucosamine/chondroitin in arthritic dogs. Toxicol Mech Methods. PubMed · DOI — 20 dogs, 120 days; 62% pain reduction, 91% limb manipulation improvement.
2. Gencoglu H, et al. (2020). UC-II in Companion Animal Joint Health: Review. Animals, 10(4):697. PMC — Oral tolerance via Peyer's patches → Treg; 10-40 mg effective dose.
3. Stabile M, et al. (2019). UC-II vs Robenacoxib in OA Dogs. Vet Sci. PMC — 60 dogs; UC-II non-inferior to NSAID.
4. Samarelli R, et al. (2024). UC-II + Boswellia in canine mobility disorders. PLoS One. PLOS — Double-blind crossover RCT.
5. Vandeweerd JM, et al. (2012). Nutraceutical efficacy systematic review in canine OA. J Vet Intern Med. PubMed — Only omega-3 well-supported; glucosamine most studied.
6. Viviano KR (2013). NAC → GSH in dogs. J Vet Intern Med. PubMed — GSH as protein oxidation defense.

---

N14 — BDC: Genomic Stability & Cellular Resilience

Biological role. This subsystem models four pathways: DNA repair cofactors, methylation/epigenetic substrates, senolytic pathway, and telomere protection. The methylation/epigenetic pathway has exceptional substrate depth with five inputs (folate, B12, B6, SAMe, spermidine) feeding into the one-carbon metabolism cycle that generates S-adenosylmethionine for DNMT-mediated DNA methylation. Omega-3 fatty acids show an inverse correlation between omega-3 index and telomere shortening rate, providing dietary-accessible telomere protection. The senolytic pathway is engaged by fisetin and quercetin at daily maintenance doses, though these are below validated rodent senolytic doses (~100 mg/kg) and therefore sub-threshold for validated clearance of senescent cells.

Claims supported.

• Four pathways: DNA repair cofactors, methylation/epigenetic substrates, senolytic pathway, telomere protection
• Methylation pathway has exceptional depth: five inputs (folate, B12, B6, SAMe, spermidine)
• EPA/DHA: omega-3 index inversely correlated with telomere shortening rate [B]
• Fisetin and quercetin engage senolytic pathway at maintenance doses — below validated senolytic threshold
• Senolytic dosing in daily supplementation is sub-threshold for validated senescent cell clearance
• Canine epigenetic clock provides methylation-based genomic stability readout [B]

Where this fits.

• → Parent system: System 5 (N07), System 4 (N06)
• → Ingredients: B-Vitamins (N16), SAMe (N34), Fisetin/Spermidine (N29), Quercetin (N22), EPA/DHA (N26)
• → Cross-reference: Nutrient Sensing (N12) — sirtuin/NAD⁺ overlaps with epigenetic modulation
• → Scoring: BDC Scoring Methodology (N36)
• → Site architecture: /evidence/bdc-genomic-stability

Primary literature.

1. Yousefzadeh MJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PubMed · DOI — Most potent of 10 flavonoids; 25-50% senescent cell clearance.
2. Watowich MM, et al. (2024). Senolytic + NAD+ precursor in senior dogs. Sci Rep. Nature — 70-dog RCT; 88.9% cognitive improvement.
3. Lorke et al. (2020). Omega-3 + antioxidants on telomere length in old dogs. Res Vet Sci. PubMed · DOI — Enriched diet improved minimum telomere length in old dogs.
4. Ali et al. (2022). Omega-3 and telomere length: meta-analysis. Clin Nutr ESPEN. PubMed · DOI — Significant positive effect (p=0.02).
5. Thompson MJ, et al. (2017). Canine epigenetic clock. Aging. PubMed — Methylation as genomic stability readout.
6. Park S, Kang S (2023). One-carbon metabolism and DNA methylation. Nutr Res Pract. PMC — Folate/B12/B6 → SAM → methylation maintenance.
7. Fick LJ, et al. (2012). Telomere length and breed lifespan. Cell Rep. PubMed — 175 dogs; telomere length predicts lifespan.

---

Tier D — Key Ingredients

---

N15 — NR / NMN / NAD⁺ Precursors

Biological role. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are direct NAD⁺ precursors that enter the salvage pathway via NRK1/NRK2 and NMNAT enzymes. NAD⁺ levels decline with age, reducing sirtuin (SIRT1–7) deacetylase activity and impairing DNA repair, metabolic regulation, and stress resistance. CD38-mediated NAD⁺ degradation increases with age, accelerating the decline. A 70-dog RCT demonstrated cognitive improvement with a NAD⁺ precursor + senolytic combination. However, canine-specific oral pharmacokinetics for NR and NMN remain sparse (PK2–PK3), and the gut microbiome mediates NR/NMN metabolism in ways that are poorly characterized across species.

Claims supported.

• NR is a direct NAD⁺ precursor targeting the sirtuin/NAD⁺ pathway
• NAD⁺ levels decline with age, reducing sirtuin activity and impairing DNA repair and metabolic regulation
• 70-dog RCT demonstrated cognitive improvement with NAD⁺ precursor + senolytic [A]
• Canine oral PK sparse (PK2–PK3); gut microbiome mediates NR/NMN metabolism
• Breed-specific SIRT6 splicing variants may modulate IGF-1 pathway responsiveness

Where this fits.

• → Parent system: System 1 (N03) — sirtuin/NAD⁺ pathway
• → BDC Subsystem: Nutrient Sensing & Autophagy (N12) — sirtuin/NAD⁺ pathway gap
• → Cross-reference: B-Vitamins (N16) — B3/niacin as alternative NAD⁺ precursor
• → Site architecture: /ingredients/nad-precursors

Primary literature.

1. Watowich MM, et al. (2024). NAD+ precursor + senolytic in senior dogs. Sci Rep. Nature — 70-dog RCT; cognitive improvement.
2. Imai S, Guarente L (2014). NAD+ and sirtuins. Trends Cell Biol. PubMed — NAD+ decline → sirtuin inactivation.
3. Verdin E (2015). NAD+ in aging. Science. — Central metabolic cofactor declining with age.
4. Mehmel M, et al. (2020). Nicotinamide Riboside: research and therapeutic uses. Nutrients. PMC — NR safety up to 2g; NAD+ pathways.
5. Irie J, et al. (2022). NMN safety in healthy subjects. Front Nutr. — Oral NMN safely increases blood NAD+.
6. Yang H, et al. (2025). NMN vs NR comparison. Food Frontiers. — Head-to-head review.
7. Özmen et al. (2025). SIRT6 and canine longevity. BMC Genomics. PMC — Breed-specific SIRT6 variants.

---

N16 — B-Vitamins (B2, B3, B6, B12, Folate)

Biological role. B-vitamins function as essential coenzymes across multiple aging-relevant pathways. Riboflavin (B2) is the FAD cofactor for ETC Complexes I/II and glutathione reductase. Niacin (B3) is an NAD⁺ synthesis precursor via the Preiss-Handler pathway. Pyridoxine (B6) is the transsulfuration pathway cofactor enabling cystathionine beta-synthase activity. Cobalamin (B12) is the methionine synthase cofactor for one-carbon metabolism. Folate drives the folate cycle, generating methyl groups for DNA methylation via SAM. All B-vitamins have established oral absorption in dogs (PK1). Standard kibble provides AAFCO-minimum levels, but aging dogs may benefit from above-minimum supplementation to support declining metabolic efficiency.

Claims supported.

• B2 is FAD cofactor for ETC Complexes I/II and glutathione reductase [B/PK1]
• B3 is NAD⁺ synthesis precursor [D/PK1]
• B6 is transsulfuration pathway cofactor [C/PK1]
• B12 is methionine synthase cofactor for one-carbon metabolism [C/PK1]
• All B-vitamins have established oral absorption in dogs (PK1)
• Folate deficiency causes uracil misincorporation during DNA synthesis

Where this fits.

• → Parent system: System 1 (N03), System 5 (N07)
• → BDC Subsystems: Mitochondrial Integrity (N09) — ETC cofactor supply; Genomic Stability (N14) — methylation substrates
• → Cross-reference: NR/NMN (N15) — B3/niacin as alternative NAD⁺ precursor; SAMe (N34) — one-carbon cycle
• → Site architecture: /ingredients/b-vitamins

Primary literature.

1. Park S, Kang S (2023). One-carbon metabolism and DNA methylation. Nutr Res Pract. PMC — Folate/B12/B6 → SAM → methylation.
2. Zheng Y, et al. (2020). B Vitamins and One-Carbon Metabolism. Nutrients. PMC — B2 as MTHFR cofactor; folate deficiency → DNA breaks.
3. Suchodolski JS, et al. (2023). Cobalamin Information. Texas A&M GI Lab. TAMU — Canine B12 absorption and supplementation.
4. NRC (2006). Nutrient Requirements of Dogs and Cats. — B-vitamin minimum/recommended intakes.
5. Head E, et al. (2021). Nutrients, Cognition, Brain Aging in Dogs. Med Sci. PMC — B-vitamin fortification in cognitive diets.
6. Papich MG, Martinez MN (2019). Human-Canine Oral Bioavailability. AAPS J. PubMed — B-vitamins generally PK1 in dogs.

---

N17 — Glutathione & NAC

Biological role. Glutathione (GSH) is the most abundant intracellular antioxidant, critical for Phase II conjugation reactions, protein oxidation defense, and redox homeostasis. GSH levels decline significantly with age. NAC (N-acetylcysteine) provides the rate-limiting cysteine substrate for GSH synthesis via gamma-glutamylcysteine synthetase. NAC has established veterinary use for acetaminophen toxicity rescue, but chronic oral supplementation data in dogs are limited. S-acetyl-glutathione (SAG) represents a bioavailability-enhanced direct GSH form that has shown increased erythrocyte GSH and improved liver biochemistry in canine trials. The oral bioavailability of unmodified GSH in dogs remains uncertain (PK3).

Claims supported.

• GSH is the most abundant intracellular antioxidant; levels decline significantly with age
• NAC is the rate-limiting cysteine donor for glutathione synthesis
• NAC has established veterinary use for acetaminophen toxicity; chronic oral data limited [C/D]
• SAG (S-acetyl-glutathione) increased erythrocyte GSH in canine liver disease trial (24 dogs)
• SAG modulated GPx activity via GSH substrate availability in healthy dogs
• Oral bioavailability of unmodified GSH uncertain in dogs (PK3)

Where this fits.

• → Parent system: System 3 (N05)
• → BDC Subsystem: Oxidative Defense (N10) — GSH synthesis pathway
• → Cross-reference: SAMe (N34) — transsulfuration to cysteine → GSH; Vitamins C & E (N20) — redox recycling
• → Site architecture: /ingredients/glutathione-nac

Primary literature.

1. Viviano KR (2013). NAC in hospitalized ill dogs. J Vet Intern Med. PubMed — 60 dogs; NAC maintained GSH; illness depletes GSH.
2. Martello et al. (2023). SAG + Silybin in canine liver disease. Vet Sci. PMC — 24 dogs; increased GSH, reduced liver enzymes.
3. Hagen A, et al. (2019). NAC/SAMe/silybin/vitamin E in ill dogs. J Small Anim Pract. PubMed — Combined hepatoprotective approach.
4. Center SA (2021). SAMe in veterinary hepatoprotection. — Trans-sulfuration → cysteine → GSH.

---

N18 — CoQ10 (Ubiquinone/Ubiquinol)

Biological role. Coenzyme Q10 functions as a mobile electron carrier between Complex I/II and Complex III in the mitochondrial electron transport chain. It exists in two redox states: ubiquinone (oxidized) and ubiquinol (reduced), with ubiquinol showing superior oral absorption. CoQ10 biosynthesis declines with age, reducing ETC efficiency. In dogs, a canine MMVD RCT demonstrated dose-dependent plasma CoQ10 increases, and beagle safety studies showed no adverse effects with chronic supplementation. CoQ10 also functions as a lipid-phase antioxidant in mitochondrial membranes. The form-dependent absorption profile warrants PK2 classification.

Claims supported.

• CoQ10 is a mitochondrial ETC cofactor (Complex I/II→III electron carrier); levels decline with age
• Ubiquinol (reduced form) shows superior oral absorption compared to ubiquinone
• Canine MMVD RCT: dose-dependent plasma CoQ10 increases in 30 dogs
• Beagle safety studies: no adverse effects with chronic supplementation
• Lipid-phase antioxidant function in mitochondrial membranes
• Form-dependent absorption → PK2 classification

Where this fits.

• → Parent system: System 3 (N05), System 6 (N08) — cardiac support
• → BDC Subsystem: Mitochondrial Integrity (N09) — ETC cofactor supply
• → Cross-reference: L-Carnitine (N33) — complementary mitochondrial support; Vitamins C & E (N20) — antioxidant recycling via Nrf2
• → Site architecture: /ingredients/coq10

Primary literature.

1. Schulz C, et al. (2011). CoQ10 and cognition in statin-treated dogs. Neurosci Lett. PMC — CoQ10 depletion and cognition.
2. Ikematsu H, et al. (2006). CoQ10 safety in beagles. Int J Toxicol. PMC — No adverse effects chronically.
3. Hernandez-Camacho JD, et al. (2018). CoQ10 in aging and disease. Front Physiol. — ETC cofactor; age-related decline.
4. Head E, et al. (2009). Brain mitochondria in canine aging. Exp Neurol. PMC — Aged brain mito dysfunction.

---

N19 — Astaxanthin

Biological role. Astaxanthin is a xanthophyll carotenoid with potent lipid-soluble antioxidant properties. Uniquely among dietary antioxidants, it crosses both the blood-brain barrier and the blood-retinal barrier, enabling neuroprotective and retinal-protective effects. Its membrane-spanning molecular orientation provides lipid peroxidation chain-breaking capacity superior to beta-carotene for singlet oxygen quenching. Astaxanthin also activates Nrf2, functioning as both a direct antioxidant and an endogenous antioxidant system inducer. Canine studies demonstrate dose-dependent subcellular uptake (PK1 confirmed in 48 dogs) and suppressed lipid peroxidation with improved liver parameters.

Claims supported.

• Uniquely crosses blood-brain barrier and blood-retinal barrier among dietary carotenoids
• Membrane-spanning antioxidant orientation; singlet oxygen quenching superior to beta-carotene
• Canine RCT (15 dogs): suppressed lipid peroxidation, improved liver parameters
• Dose-dependent uptake confirmed in 48 dogs (PK1)
• Dual function: direct lipid-phase antioxidant + Nrf2 activator

Where this fits.

• → Parent system: System 3 (N05)
• → BDC Subsystem: Oxidative Defense (N10) — lipid-phase protection pathway
• → Cross-reference: Vitamins C & E (N20) — complementary lipid-phase protection; Blueberry (N21) — polyphenol antioxidants
• → Site architecture: /ingredients/astaxanthin

Primary literature.

1. Park JS, et al. (2019). ASX supplementation in healthy and obese dogs. Vet Med (Auckl). PMC — 15 dogs; suppressed lipid peroxidation; improved liver parameters.
2. Chew BP, et al. (2010). ASX uptake in domestic dogs. Vet Clin Pathol. PMC — Dose-dependent uptake; subcellular distribution confirmed (PK1).
3. Davinelli S, et al. (2021). Nrf2 as therapeutic target for ASX. Biomed Pharmacother. — Dual Nrf2 activator + direct antioxidant.
4. Galasso C, et al. (2018). Neuroprotective role of ASX. Mar Drugs. PMC — BBB crossing; neuroprotection.

---

N20 — Vitamins C & E

Biological role. Vitamin E (mixed tocopherols) is the primary lipid-phase chain-breaking membrane antioxidant, terminating lipid peroxidation chain reactions by donating a hydrogen atom. Vitamin C (ascorbate) is a water-phase antioxidant that regenerates oxidized vitamin E and serves as an essential cofactor for prolyl/lysyl hydroxylase in collagen synthesis. Dogs synthesize vitamin C endogenously, but supplementation may benefit stressed, ill, or aging animals whose synthesis rates are insufficient for demand. Vitamin E also modulates inflammatory gene expression at the transcriptional level via NF-kB and AP-1 suppression. Both vitamins have PK1 classification in dogs.

Claims supported.

• Vitamin E is the primary lipid-phase chain-breaking membrane antioxidant [B/PK1]
• Vitamin C regenerates oxidized vitamin E and is a collagen synthesis cofactor [B/PK1]
• Dogs synthesize vitamin C endogenously; supplementation may benefit stressed/aging dogs
• Vitamin E modulates inflammatory gene expression at transcriptional level [B]
• 40-dog RCT: vitamin E/C/beta-carotene blend enhanced antioxidant protection
• High-dose vitamin E supplementation in some human trials associated with increased mortality — balance matters

Where this fits.

• → Parent system: System 3 (N05), System 2 (N04)
• → BDC Subsystem: Oxidative Defense (N10) — lipid-phase protection, GSH synthesis pathways
• → Cross-reference: Astaxanthin (N19) — complementary lipid-phase protection; Glutathione/NAC (N17) — redox cycling
• → Proteostasis (N13): vitamin C as collagen synthesis cofactor
• → Site architecture: /ingredients/vitamins-c-e

Primary literature.

1. Surai PF, et al. (2024). Dietary antioxidants in dogs. J Anim Sci. PMC — 40 dogs, 84 days; E/C/beta-carotene enhanced protection.
2. Hesta M, et al. (2009). Vitamin C supplementation in healthy dogs. J Anim Physiol Anim Nutr. PubMed · DOI — Antioxidative capacity and immune effects.
3. Cotman CW, et al. (2002). Antioxidant-enriched diet and canine brain aging. Neurobiol Aging. — Beagles; reduced cognitive dysfunction.
4. Zafalon RVA, et al. (2020). Vitamin C in Companion Animals. Top Companion Anim Med. — Canine synthesis rate; sodium ascorbate bioavailability.
5. Sechi et al. (2017). Antioxidants in therapy dogs. BMC Vet Res. PMC — 11 dogs; reduced oxidative stress markers.

---

N21 — Blueberry / Anthocyanins

Biological role. Blueberry powder provides anthocyanin polyphenols — water-soluble flavonoid pigments with antioxidant, anti-inflammatory, and neuroprotective properties. Anthocyanins cross the blood-brain barrier and localize in memory-relevant brain regions (hippocampus, cortex). In aged beagles, a polyphenol-enriched grape and blueberry extract (PEGB) increased SOD mRNA expression and produced detectable polyphenol metabolites in plasma (35 dogs, RCT). Anthocyanin antioxidant capacity is well-demonstrated in vitro, but in vivo canine bioavailability is limited (PK2–PK3) due to rapid Phase II metabolism and low systemic exposure.

Claims supported.

• Anthocyanins cross the blood-brain barrier and localize in memory-relevant brain regions
• PEGB beagle RCT (35 dogs): increased SOD mRNA; polyphenol metabolites in plasma
• Antioxidant-enriched diet reduced cognitive dysfunction in aged beagles within 2 weeks
• In vivo canine bioavailability limited (PK2–PK3) due to rapid Phase II metabolism
• Primary system: oxidative stress defense; secondary: neuroprotection

Where this fits.

• → Parent system: System 3 (N05), System 6 (N08) — cognitive domain
• → BDC Subsystem: Oxidative Defense (N10)
• → Cross-reference: Astaxanthin (N19) — complementary neuroprotective antioxidant; Quercetin (N22) — flavonoid class
• → Site architecture: /ingredients/blueberry-anthocyanins

Primary literature.

1. Fragua V, et al. (2017). Effects of dietary supplementation with a mixed blueberry and grape extract on working memory in aged beagle dogs. J Nutr Sci. PMC — 35 aged beagles; PEGB increased SOD mRNA; polyphenol metabolites in plasma.
2. Cotman CW, et al. (2002). Antioxidant-enriched diet reduces cognitive dysfunction in canines. Neurobiol Aging. — Aged beagles; cognition improved within 2 weeks.
3. Maturana M et al. (2025). Effects of Blueberry Consumption on Preference, Digestibility, and Oxidative Balance in Dogs. Animals (Basel). PubMed · DOI — 12 Beagles, 4-wk 3% blueberry diet. Null result: BLU diet did not mitigate exercise-induced increases in CK or MDA, or decrease in GPx. Funded by Visán (pet food manufacturer).

---

N22 — Quercetin

Biological role. Quercetin is a ubiquitous flavonoid with multiple aging-relevant mechanisms: NF-kB pathway inhibition, NLRP3 inflammasome modulation, mast cell stabilization, AMPK activation, and modest senolytic activity via p16^INK4a-positive cell clearance in rodent models. Canine PK demonstrates low oral bioavailability for quercetin aglycone (3.6%), with isoquercitrin (glycoside form) showing higher absorption. Dogs have functional hepatic glucuronidation capacity, permitting quercetin metabolism (unlike cats, where glucuronidation is impaired). At daily maintenance doses, quercetin functions primarily as an anti-inflammatory compound rather than a senolytic — validated rodent senolytic doses (~100 mg/kg) are far above supplemental concentrations.

Claims supported.

• NF-kB/NLRP3 inflammasome modulation and mast cell stabilization [C/D]
• Modest senolytic properties in rodent models [D for senolytic; C for anti-inflammatory]
• Canine PK: quercetin aglycone 3.6% bioavailability; isoquercitrin form higher (PK2)
• Present at daily maintenance dose, not at intermittent high-dose senolytic protocol concentrations
• Dogs have functional hepatic glucuronidation (unlike cats)
• 70-dog RCT included quercetin in senolytic + NAD⁺ combination; cognitive improvement [A]

Where this fits.

• → Parent system: System 2 (N04), System 4 (N06), System 1 (N03)
• → BDC Subsystems: Inflammaging (N11) — NF-kB modulation; Genomic Stability (N14) — senolytic pathway; Nutrient Sensing (N12) — AMPK activation
• → Cross-reference: Fisetin/Spermidine (N29) — senolytic class; Curcumin (N27) — NF-kB modulation
• → Site architecture: /ingredients/quercetin

Primary literature.

1. Reinboth M, et al. (2010). Oral bioavailability of quercetin from different quercetin glycosides in dogs. J Agric Food Chem. PubMed · DOI — Canine PK: aglycone 3.6% bioavailability; isoquercitrin higher.
2. Watowich MM, et al. (2024). Senolytic + NAD+ precursor in senior dogs. Sci Rep. Nature — 70-dog RCT; 88.9% cognitive improvement.
3. Beynen AC (2020). Quercetin for dogs. ResearchGate preprint. — Anti-inflammatory, antioxidant, antihistamine; bioavailability challenges.

---

N23 — Beta Glucans

Biological role. Beta-1,3/1,6-glucans are polysaccharides that activate innate immune cells via the Dectin-1 pattern-recognition receptor on macrophages and dendritic cells. This triggers trained immunity — epigenetic reprogramming of innate immune cells for enhanced pathogen response. Canine Dectin-1 has structural differences from human Dectin-1, with linear beta-glucans showing greater effectiveness in dogs. The immune modulation operates through a gut-mediated mechanism; systemic absorption is not required. Five canine studies demonstrate trained immunity induction, increased IgA/IgM production, enhanced vaccine responses, and modulated gut microbiota. Beta glucans may interfere with immunosuppressive protocols, representing a contraindication.

Claims supported.

• Dectin-1 receptor-mediated immune modulation; canine Dectin-1 has structural differences from human [B/C/PK2]
• Trained immunity: epigenetic reprogramming of innate immune cells
• Gut-mediated mechanism; systemic absorption not required
• Beagle study: increased IgM, modulated IgA after oral beta-glucan
• Puppy RCT: increased phagocytosis (p<0.001), accelerated antibody titers
• May interfere with immunosuppressive protocols (contraindication)

Where this fits.

• → Parent system: System 2 (N04)
• → BDC Subsystem: Inflammaging (N11) — immune calibration pathway
• → Cross-reference: Reishi (N24) — overlapping Dectin-1 pathway via polysaccharide component; Spirulina (N25) — immune modulation
• → Site architecture: /ingredients/beta-glucans

Primary literature.

1. Paris et al. (2020). Beta-Glucan-Induced Trained Immunity in Dogs. Front Immunol. PMC — Canine Dectin-1 structural differences; linear beta-glucans more effective.
2. Stuyven E, et al. (2010). Oral Administration of Beta-1,3/1,6-Glucan to Dogs Temporally Changes Total and Antigen-Specific IgA and IgM. Clin Vaccine Immunol. PMC — Beagles; increased IgM, modulated IgA.
3. Amaral et al. (2024). Translating Beta-Glucans for Veterinary Care. Vet Sci. PMC — Dermatitis (63% improvement), OA, IBD applications.

---

N24 — Reishi (Ganoderma lucidum)

Biological role. Reishi (Ganoderma lucidum) contains two bioactive fractions with distinct mechanisms: triterpenes (ganoderic acids) that modulate NF-kB signaling, and polysaccharides (beta-glucans) that activate Dectin-1-mediated immune modulation. A 40-beagle dose-response RCT demonstrated increased MHC-II expression and phagocytic activity at 15 mg/kg. Triterpenes also exhibit hepatoprotective properties. Oral bioavailability of the active triterpene fraction is unknown in dogs (PK3), and reishi may interfere with immunosuppressive therapy, representing a contraindication similar to beta glucans.

Claims supported.

• Dual bioactive fractions: triterpenes (NF-kB modulation) + polysaccharides (Dectin-1 immune modulation)
• 40-beagle RCT: 15 mg/kg increased MHC-II and phagocytosis (dose-response)
• Oral bioavailability unknown in dogs (PK3)
• May interfere with immunosuppressive therapy (contraindication)
• Triterpene hepatoprotective properties documented

Where this fits.

• → Parent system: System 2 (N04)
• → Cross-reference: Beta Glucans (N23) — shared Dectin-1 pathway via polysaccharide component; Curcumin (N27) — NF-kB modulation
• → Site architecture: /ingredients/reishi

Primary literature.

1. Kayser et al. (2024). Functional properties of Ganoderma lucidum supplementation in canine nutrition. J Anim Sci. PMC — 40 beagles; 15 mg/kg increased MHC-II and phagocytosis.

---

N25 — Spirulina / Phycocyanin

Biological role. Spirulina provides phycocyanin — a biliprotein with potent anti-inflammatory and antioxidant activity. Phycocyanin selectively inhibits COX-2 with an IC50 of 80 nM (highly selective over COX-1), suppresses NF-kB signaling, and induces heme oxygenase-1. A 30-dog, 42-week RCT demonstrated enhanced vaccine response, increased fecal IgA, and improved gut microbiota stability with spirulina supplementation. A systematic review and meta-analysis of 22 studies (5,385 participants) confirmed significant reductions in CRP, IL-6, TNF-α, and MDA. Systemic bioavailability of phycocyanin is poorly characterized in dogs (PK3).

Claims supported.

• Phycocyanin selectively inhibits COX-2 (IC50 = 80 nM); highly selective over COX-1
• 30-dog RCT (42 weeks): enhanced vaccine response, fecal IgA increase, gut microbiota stability [A]
• Systematic review (22 studies, 5385 participants): CRP, IL-6, TNF-α, MDA all significantly reduced
• NF-kB suppression and heme oxygenase-1 induction
• Systemic bioavailability poorly characterized in dogs (PK3)

Where this fits.

• → Parent system: System 2 (N04), System 3 (N05)
• → BDC Subsystem: Inflammaging (N11)
• → Cross-reference: Curcumin (N27) — NF-kB modulation; EPA/DHA (N26) — anti-inflammatory
• → Site architecture: /ingredients/spirulina

Primary literature.

1. Satyaraj et al. (Nestlé Purina) (2021). Supplementation of Diets With Spirulina Influences Immune and Gut Function in Dogs. Front Nutr. PubMed · DOI — 30 dogs, 42 weeks; enhanced vaccine response, fecal IgA, gut microbiota stability.
2. Romay C, et al. (2003). C-phycocyanin: a biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr Protein Pept Sci. PubMed · DOI — 12 experimental inflammation models; dose-dependent effects.
3. Reddy CM, et al. (2000). Selective inhibition of cyclooxygenase-2 by C-phycocyanin. Biochem Biophys Res Commun. PubMed · DOI — COX-2 IC50 = 80 nM; selective over COX-1.
4. Liu et al. (2022). Phycocyanin: Anti-inflammatory effect and mechanism. Biomed Pharmacother. PubMed · DOI — NF-kB suppression, heme oxygenase-1 induction.

---

N26 — EPA/DHA Marine Omega-3s

Biological role. EPA and DHA are long-chain omega-3 polyunsaturated fatty acids that function as the multi-system backbone of canine geroscience nutrition. EPA provides resolvin E1 precursor; DHA provides resolvin D1 and protectin D1 precursors — specialized pro-resolving mediators that actively terminate inflammation. EPA/DHA competitively displace arachidonic acid from COX/LOX pathways, shifting eicosanoid production from pro-inflammatory (PGE2, LTB4) toward anti-inflammatory/pro-resolving profiles. They remodel mitochondrial cardiolipin, improving membrane fluidity and ETC coupling efficiency. Omega-3 index inversely correlates with telomere shortening rate. EPA/DHA is the only nutritional input with Grade A evidence across multiple aging systems (dermatitis, OA, cardiac, renal), supported by a 23-study systematic review and dose-optimization reviews establishing 50–100 mg/kg/day for meaningful inflammatory modulation.

Claims supported.

• Only nutritional input with Grade A evidence across multiple aging systems (OA, dermatitis, cardiac, renal)
• 23-study systematic review confirms benefit; dose-optimization: 50–100 mg/kg/day EPA [A]
• EPA provides resolvin E1; DHA provides resolvin D1 and protectin D1 precursors
• Cardiolipin remodeling improves mitochondrial membrane fluidity and ETC coupling [A]
• Omega-3 index inversely correlated with telomere shortening rate [B]
• Multi-system backbone: System 1 (insulin sensitivity), System 2 (SPMs), System 3 (membrane protection), System 6 (joints/brain/kidney/heart)

Where this fits.

• → All six control systems (N03–N08): multi-system backbone
• → BDC Subsystems: Inflammaging (N11) — SPM synthesis; Mitochondrial Integrity (N09) — membrane composition; Genomic Stability (N14) — telomere protection
• → Tier-1 Lever (N01): nutritional Tier-1 intervention
• → Cross-reference: Curcumin (N27) — complementary anti-inflammatory; Vitamins C & E (N20) — membrane protection
• → Site architecture: /ingredients/epa-dha-omega-3
• → ⚠️ Requires dedicated fish oil supplementation — dose-dependent effects demand caloric contribution

Primary literature.

1. Magalhães TR, et al. (2021). Therapeutic Effect of EPA/DHA Supplementation in Companion Animal Diseases: Systematic Review. In Vivo. PMC — 23 RCTs (20 canine); benefit in dermatitis, OA, valvular disease.
2. Lourenço AL, et al. (2025). Efficacy and optimal dosages of omega-3 supplementation for companion animals. Nutr Res Rev. PubMed — Dose ranges: OA 48-100 mg/kg EPA; anti-inflammatory ratio 1:3.75.
3. Mueller RS, et al. (2004). Effect of omega-3 fatty acids on canine atopic dermatitis. Can Vet J. PubMed · DOI — 29 dogs, double-blind RCT; EPA 50 mg/kg/day improved clinical scores.
4. Mehler SJ, et al. (2016). Effects of EPA and DHA on clinical signs in dogs with osteoarthritis. Prostaglandins Leukot Essent Fatty Acids. PubMed — 78 dogs, prospective RCT; 69 mg/kg/day correlated with OA relief.
5. Brown SA, et al. (1998). Beneficial effects of dietary omega-3 PUFAs in dogs with renal insufficiency. J Lab Clin Med. PubMed · DOI — Renoprotective; reduced proteinuria.
6. Brown SA, et al. (2000). Dietary PUFA supplementation in early renal insufficiency in dogs. J Lab Clin Med. PubMed · DOI — Omega-3 renoprotective vs omega-6 harmful.
7. Freeman LM (2010). Beneficial effects of omega-3 fatty acids in cardiovascular disease. J Vet Intern Med. — Canine cardiac: reduced arrhythmia, anti-inflammatory in DMVD.
8. Carlisle et al. (2024). Omega-3 Supplementation: Omega-3 Index, Quality of Life and Pain Scores in Dogs. Animals. PMC — 68 mg/kg/day; O3I 1.4→3.3%; pain scores declined (p=0.012).

---

N27 — Curcumin (Bioavailable Forms)

Biological role. Curcumin is a polyphenol from turmeric that inhibits NF-kB nuclear translocation via IκB kinase (IKK) inhibition and suppresses COX-2 transcription. Bioavailability is a critical limitation — native curcumin undergoes rapid hepatic glucuronidation, but bioenhanced formulations (phytosomes, nanoparticles) improve absorption. Two canine OA RCTs demonstrate efficacy: P54FP curcumin extract and a 42-dog double-blind trial combining curcuminoids with collagen and green tea. Phytosomal curcumin in 18 dogs significantly decreased NF-kB1, IL-8, and PTGS2 gene expression. Dogs have functional hepatic glucuronidation permitting curcumin metabolism (unlike cats). Curcumin is not included in the current formulation SKU but addresses the NF-kB modulation pathway.

Claims supported.

• NF-kB pathway modulation via IKK inhibition and COX-2 transcriptional suppression [C/D]
• Two canine OA RCTs: P54FP extract and 42-dog curcuminoid combination trial
• Phytosomal curcumin (18 dogs): decreased NF-kB1, IL-8, PTGS2 gene expression
• OA meta-analysis: TNF-α, IL-1, NF-kB, MMPs all improved (p<0.001)
• Bioavailability particularly variable despite bioenhanced formulations (PK2–PK3)
• Dogs have functional hepatic glucuronidation (unlike cats)

Where this fits.

• → Parent system: System 2 (N04)
• → BDC Subsystem: Inflammaging (N11) — NF-kB modulation pathway
• → Cross-reference: Quercetin (N22) — NF-kB modulation; EPA/DHA (N26) — complementary anti-inflammatory; Boswellia → Inflammaging (N11)
• → Site architecture: /ingredients/curcumin

Primary literature.

1. Innes JF, et al. (2003). Randomised, double-blind, placebo-controlled study of P54FP for canine osteoarthritis. Vet Rec. PubMed · DOI — Early curcumin extract RCT for canine OA.
2. Comblain F, et al. (2017). Efficacy of curcuminoids extract + collagen + green tea in dogs with OA. BMC Vet Res. PubMed · DOI — 42 dogs, double-blind RCT; significant pain reduction.
3. Caterino et al. (2021). Curcuvet + Boswellic acid in canine OA. PLoS One / Vet Sci. PMC — Phytosomal curcumin synergy; TNF-alpha, NF-kB1 decreased.
4. Sgorlon S, et al. (2016). Phytosome curcumin in dogs with OA. — 18 dogs; NF-kB1, IL-8, PTGS2 decreased.

---

N28 — Resveratrol

Biological role. Resveratrol is a stilbene polyphenol proposed as a calorie-restriction mimetic via SIRT1 allosteric activation and AMPK pathway engagement. In dogs, a CVD review describes SIRT1-AMPK pathway activation, cardiac remodeling modulation, and anti-inflammatory effects. A canine immunomodulation study showed dose-dependent increases in phagocytosis and modulated oxidative burst. However, resveratrol undergoes rapid hepatic glucuronidation and sulfation during first-pass metabolism, resulting in very low systemic bioavailability. Canine PK is unknown (PK3), making systemic exposure highly uncertain. The SIRT1 activation mechanism remains debated in the literature.

Claims supported.

• AMPK/sirtuin modulator proposed as calorie-restriction mimetic [D/PK3]
• Canine CVD review: SIRT1-AMPK pathway, cardiac remodeling, anti-inflammatory
• Canine immunomodulation study: dose-dependent phagocytosis increase
• Rapid hepatic metabolism results in very low bioavailability; canine PK unknown (PK3)
• SIRT1 activation mechanism remains debated

Where this fits.

• → Parent system: System 1 (N03) — sirtuin/AMPK
• → BDC Subsystem: Nutrient Sensing (N12) — sirtuin/NAD⁺ and AMPK pathways
• → Cross-reference: NR/NMN (N15) — sirtuin activation via NAD⁺; Quercetin (N22) — AMPK activation
• → Site architecture: /ingredients/resveratrol

Primary literature.

1. Grzeczka et al. (2024). Pleiotropic Effects of Resveratrol on Aging-Related CVD in Dogs. Cells. PubMed · DOI — SIRT1-AMPK pathway, cardiac remodeling, anti-inflammatory.
2. Mathew et al. (2018). Resveratrol increases phagocytosis, modulates oxidative burst in healthy dogs. Vet Immunol Immunopathol. PubMed · DOI — Dose-dependent immunomodulation.
3. Pastor RF, et al. (2019). Resveratrol + alpha-Tocopherol supplementation and sarcopenia risk in dogs. Nutr Health Aging. — SIRT1-mediated mitochondrial biogenesis.
4. Rogina et al. (2024). SIRT1, resveratrol and aging. Mech Ageing Dev. PubMed · DOI — Calorie restriction mimetic via sirtuin activation.

---

N29 — Fisetin & Spermidine (Senolytics/Autophagy)

Biological role. Fisetin is a flavonoid that has demonstrated potent senolytic activity in rodent models — clearance of p16^INK4a/p21-positive senescent cells with 25–50% reduction, extending healthspan. It was the most potent of 10 flavonoids screened in a systematic comparison. Spermidine is a polyamine that induces autophagy via EP300 acetyltransferase inhibition, a mechanism independent of mTOR. Spermidine levels decline with age, and supplementation extends lifespan across multiple model organisms. Neither compound has canine efficacy, safety, or PK data — all evidence is translational (rodent/human). Both are outside the current formulation SKU and carry a Grade D evidence ceiling for canine application.

Claims supported.

• Fisetin: most potent of 10 flavonoids for senolytic activity in rodent models; 25–50% senescent cell clearance [D]
• No canine efficacy, safety, or PK data exists for fisetin
• Spermidine: direct autophagy inducer via EP300 acetyltransferase inhibition [C/D]
• Spermidine associated with longevity in rodent and observational human studies
• Both are outside current formulation SKU
• Grade D evidence ceiling for canine application — all translational

Where this fits.

• → Parent system: System 4 (N06), System 1 (N03)
• → BDC Subsystems: Genomic Stability (N14) — senolytic pathway; Nutrient Sensing (N12) — autophagy induction
• → Cross-reference: Quercetin (N22) — senolytic class comparison
• → Site architecture: /ingredients/fisetin-spermidine
• → ⚠️ No canine data — Grade D ceiling; flag for future research monitoring

Primary literature.

1. Yousefzadeh MJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PubMed — Most potent of 10 flavonoids; p16/p21/SASP clearance; extended healthspan.
2. Murray et al. (2025). Intermittent Fisetin Improves Physical Function and Decreases Cellular Senescence in Aging Skeletal Muscle. J Gerontol A. PubMed · DOI — Comparable to genetic p16+ clearance and ABT-263.
3. Eisenberg T, et al. (2009). Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. PubMed · DOI — Cross-species autophagy induction; age-related decline.
4. Madeo F, et al. (2010). Spermidine: a novel autophagy inducer and longevity elixir. Autophagy. PubMed · DOI — EP300 acetyltransferase inhibition mechanism.

---

N30 — Joint & ECM Substrates: LPL-01 Actives (Collagen Peptides, HA, MSM, Gelatin, Bone Broth) and Comparative Context (⊘ Glucosamine, ⊘ UC-II)

Biological role. Joint and ECM substrate science encompasses two mechanistically distinct categories that must be clearly distinguished for LPL-01 attribution accuracy. Category 1 — LPL-01 actives via Pet Gala: Marine Collagen Peptides (500 mg), Hydrolyzed Whey Protein (250 mg), Beef Gelatin (200 mg), Bone Broth (100 mg), Hyaluronic Acid (50 mg), and MSM (100 mg). These are current formulation ingredients. Hydrolyzed collagen peptides and gelatin provide pre-formed proline/hydroxyproline/glycine (comprising ~57% of the collagen molecule by weight) — bypassing de novo fibroblast amino acid synthesis. HA is the primary hygroscopic macromolecule of synovial fluid and dermal ECM. MSM provides bioavailable organic sulfur (34% sulfur by mass) for proteoglycan and connective tissue synthesis. Category 2 — ⊘ Comparative context (NOT in LPL-01): UC-II (undenatured type II collagen, 40 mg) operates via a categorically distinct oral immune tolerance mechanism — Peyer's patch sampling triggers Treg modulation downregulating autoimmune cartilage attack. Four canine RCTs demonstrate UC-II efficacy including non-inferiority to NSAIDs and superiority to glucosamine by objective ground-force plate measurement. Glucosamine HCl provides UDP-GlcNAc precursor for GAG biosynthesis but shows no significant benefit in the meta-analysis of 72 canine OA trials — and is not included in the formulation. These two contextual ingredients are documented here because they appear throughout the joint health literature and are referenced in this framework.

Claims supported.

• LPL-01 (Pet Gala): Marine collagen peptides provide pre-formed proline/hydroxyproline/glycine — bypasses de novo synthesis for fibroblast ECM production [B]
• LPL-01 (Pet Gala): Hydrolyzed whey adds high-BV amino acid supply (BV ~104) including cysteine for GSH [B]
• LPL-01 (Pet Gala): Beef gelatin — proline-rich structural protein; complementary collagen precursor pool [B]
• LPL-01 (Pet Gala): Bone broth — mineral matrix (Ca, P, Mg, trace minerals) for wound-healing cascade [B/C]
• LPL-01 (Pet Gala): Hyaluronic acid — direct GAG hydration molecule; the primary hygroscopic macromolecule of synovial fluid and dermis [B]
• LPL-01 (Pet Gala): MSM — organic sulfur donor for proteoglycan and collagen synthesis; anti-inflammatory via NF-κB/MAPK [C]
• ⊘ UC-II (NOT in LPL-01): Oral tolerance via Peyer's patches → Treg modulation; four canine RCTs [A/B]
• ⊘ UC-II (NOT in LPL-01): Non-inferior to NSAID (31.4% vs 29.5% LOAD reduction in 76-dog trial)
• ⊘ UC-II (NOT in LPL-01): Superior to glucosamine by ground-force plate measurement
• ⊘ Glucosamine (NOT in LPL-01): No significant benefit in meta-analysis of 72 canine OA trials; not included on evidence grounds
• Multimodal OA management is consensus standard of care; nutritional substrates are adjunctive
• EPA/DHA (N26) remains the strongest single nutraceutical for canine OA by 72-trial meta-analysis

Where this fits.

• → LPL-01 actives (Pet Gala): System 6 (N08) — musculoskeletal/connective tissue domain; BDC Subsystem: Proteostasis/ECM (N13) — structural matrix substrate supply
• → ⊘ Comparative context (not in LPL-01): UC-II and glucosamine are referenced in System 6 and OA management sections as contextual standards of comparison
• → Cross-reference: EPA/DHA (N26) — the strongest canine OA nutraceutical by meta-analysis; L-Carnitine (N33) — cardiac ECM-adjacent; Formulation Crosswalk (N37)
• → Site architecture: /ingredients/collagen, /ingredients/hyaluronic-acid, /ingredients/msm

Primary literature.

1. D'Altilio S, et al. (2007). Therapeutic Efficacy and Safety of UC-II in Arthritic Dogs. Toxicol Mech Methods. PubMed — 20 dogs, 120 days; 62% pain reduction, 91% manipulation pain reduction.
2. Gupta RC, et al. (2012). Comparative efficacy of UC-II vs glucosamine/chondroitin: ground force plate. J Anim Physiol Anim Nutr. PubMed · DOI — UC-II superior by objective measurement.
3. Stabile M, et al. (2022). UC-II compared to cimicoxib in 76 dogs with natural OA. Res Vet Sci. PubMed · DOI — UC-II non-inferior to NSAID (31.4% vs 29.5% LOAD reduction).
4. Stabile M, et al. (2024). UC-II + Boswellia Serrata in dogs with mild/moderate OA: RCT. PLoS One. PubMed · DOI — 60 dogs screened; double-blind crossover.
5. Barbeau-Grégoire M, et al. (2022). Systematic Review and Meta-Analysis of Nutraceuticals in Canine/Feline OA. Animals. PMC — 72 trials; glucosamine no effect; omega-3 strongest.
6. Pye C (2024). Non-pharmaceutical treatments of canine OA. J Small Anim Pract. — UC-II weak positive; glucosamine/chondroitin no benefit.

---

N31 — ⊘ MCTs (C8/C10 Caprylic/Capric Acid) — NOT in LPL-01 Formulation — Comparative Cognitive Geroscience Context

Biological role. Medium-chain triglycerides (C8 caprylic and C10 capric acid) undergo rapid hepatic beta-oxidation to acetyl-CoA, which enters ketogenesis to produce acetoacetate and beta-hydroxybutyrate. These ketone bodies provide an alternative neuronal energy substrate independent of glucose transporters, bypassing the impaired glucose metabolism characteristic of canine cognitive dysfunction. Three canine cognition RCTs demonstrate efficacy: Pan et al. (2010) showed long-lasting improvement in 24 aged beagles over 8 months, Pan et al. (2018) demonstrated improvement across all 6 CDS categories, and a canine epilepsy trial showed improved spatial-working memory and problem-solving. MCTs require caloric contribution and are not included in the current formulation SKU.

Claims supported.

• MCTs provide ketone bodies as alternative brain fuel bypassing impaired glucose metabolism [A]
• Pan et al. (2010): 24 aged beagles, 8 months; increased BHB, improved cognition [A]
• Pan et al. (2018): double-blind RCT; all 6 CDS categories improved (p<0.05) [A]
• Canine epilepsy trial: improved spatial-working memory (P=0.008), problem-solving (P=0.048) [A]
• CCD prevalence ~28% at 11–12, ~68% at 15–16; growing clinical need
• Not in current formulation SKU — requires caloric contribution

Where this fits.

• → Parent system: System 6 (N08) — cognitive domain
• → BDC Subsystem: Mitochondrial Integrity (N09) — metabolic flexibility pathway
• → Cross-reference: Blueberry (N21) — neuroprotective; Astaxanthin (N19) — BBB-crossing neuroprotection; EPA/DHA (N26) — brain DHA
• → Site architecture: /ingredients/mct-oil

Primary literature.

1. Pan Y, et al. (2010). Dietary MCT has long-lasting cognition-enhancing effects in aged dogs. Br J Nutr. PubMed — 24 aged beagles, 8 months; increased BHB, improved cognition.
2. Pan Y, et al. (2018). Therapeutic Diet efficacy on dogs with CDS. Front Nutr. PubMed · DOI — Double-blind RCT; all 6 CDS categories improved (p<0.05).
3. Berk BA, et al. (2021). MCT dietary supplement improves cognition in canine epilepsy. Epilepsy Behav. PubMed · DOI — Spatial-working memory (P=0.008), problem-solving (P=0.048).
4. Pan et al. (2024). Effects of MCT Supplementation on Serum Metabolome in Canines. Animals. PMC — Age-specific metabolic shifts.
5. Head E, et al. (2021). Nutrients, Cognitive Function, and Brain Aging in Dogs. Med Sci. — MCT as brain fuel; CCD model overview.

---

N32 — ⊘ Taurine (Standalone Supplement) — NOT in LPL-01 Formulation as Standalone — Comparative Cardiac Geroscience Context

⊘ Formulation status note: Taurine is NOT included in Hollywood Elixir or Pet Gala as a standalone ingredient. Whey Protein Isolate (HE, 250 mg) and Hydrolyzed Whey Protein (PG, 250 mg) provide taurine biosynthesis precursors (methionine, cysteine) but this is not equivalent to direct taurine supplementation and does not address DCM-associated taurine deficiency in susceptible breeds. This node is retained as critical comparative cardiac geroscience context because taurine-responsive DCM is Grade [A] canine science and appears throughout the cardiac domain of the framework.

Biological role. Taurine is a conditionally essential amino acid critical for cardiac function, mitochondrial membrane stabilization, and protein osmotic balance. In dogs, taurine deficiency causes dilated cardiomyopathy (DCM) that is reversible with supplementation — a landmark finding in veterinary cardiology. A 12-case series demonstrated 7/12 dogs alive on taurine supplementation alone, and a golden retriever study (24 dogs) showed echocardiographic normalization by 8 months. Taurine stabilizes mitochondrial membranes via osmotic buffering, modulates calcium signaling in cardiomyocytes, and conjugates bile acids. Even non-deficient dogs may benefit from supplementation given its safety profile. Grain-free diets have been associated with diet-associated DCM, potentially mediated by taurine depletion.

Claims supported.

• Taurine deficiency causes reversible DCM in susceptible breeds [A]
• 12-case DCM series: 7/12 alive on taurine alone; cardiac function improved
• Golden retriever study (24 dogs): echo normalization by 8 months on taurine
• Mitochondrial membrane stabilizer and osmotic buffer [A]
• Even non-deficient dogs may benefit from supplementation; safe
• Grain-free diet link to DCM; breed-specific taurine ranges documented
• ⊘ Not in LPL-01: whey protein precursors are not equivalent to direct taurine supplementation for DCM-susceptible breeds

Where this fits.

• → Parent system: System 6 (N08) — cardiac domain
• → BDC Subsystem: Mitochondrial Integrity (N09) — metabolic flexibility/stabilization
• → Cross-reference: L-Carnitine (N33) — complementary cardiac support; CoQ10 (N18) — mitochondrial cofactor
• → Site architecture: /ingredients/taurine

Primary literature.

1. Kittleson MD, et al. (2003). Taurine deficiency in dogs with DCM: 12 cases. JAVMA. PubMed · DOI — 7/12 alive on taurine alone; cardiac function improved.
2. Kaplan JL, et al. (2018). Taurine deficiency and DCM in golden retrievers fed commercial diets. PLoS One. PMC — 23/24 dogs improved; echo normalization by 8 months.
3. Kittleson MD, et al. (1997). Multicenter Spaniel Trial (MUST): taurine-responsive DCM. J Vet Intern Med. PubMed · DOI — 14 ACS; taurine + carnitine responsive.
4. Sanderson SL (2006). Taurine and carnitine in canine cardiomyopathy. Vet Clin North Am Small Anim Pract. PubMed · DOI — Even non-deficient dogs may benefit; safe.
5. McCauley et al. (2020). Review of canine DCM and diet-associated concerns. J Anim Sci. PMC — Grain-free diet link; breed-specific taurine ranges.

---

N33 — L-Carnitine

Biological role. L-carnitine is the mitochondrial fatty acid shuttle — the direct transporter substrate for long-chain fatty acid beta-oxidation via carnitine palmitoyltransferase I and II (CPT-I/CPT-II). It transports long-chain fatty acids across the inner mitochondrial membrane for acetyl-CoA generation. Improved fatty acid oxidation increases the AMP:ATP ratio, indirectly activating AMPK. A landmark finding in a Boxer family established the first canine carnitine-DCM link, with 17–60% of DCM dogs showing myopathic carnitine deficiency. Cardiac tissue derives approximately 60% of its energy via beta-oxidation, making carnitine critical for myocardial function. Foodomics analysis identified 5-aminovaleric acid betaine in certain diets as a carnitine transporter inhibitor.

Claims supported.

• Direct transporter substrate for beta-oxidation via CPT-I/CPT-II shuttle
• Boxer family landmark: first canine carnitine-DCM link; 17–60% DCM dogs have myopathic deficiency
• Cardiac tissue derives ~60% energy via beta-oxidation
• Improved fatty acid oxidation increases AMP:ATP ratio → indirect AMPK activation
• Foodomics: 5-aminovaleric acid betaine inhibits carnitine transporter in certain diets
• DCM meta-analysis: enhanced LCFA beta-oxidation and ATP production

Where this fits.

• → Parent system: System 1 (N03), System 6 (N08) — cardiac domain
• → BDC Subsystem: Mitochondrial Integrity (N09) — beta-oxidation pathway
• → Cross-reference: Taurine (N32) — complementary cardiac support; CoQ10 (N18) — ETC cofactor
• → Site architecture: /ingredients/l-carnitine

Primary literature.

1. Keene BW, et al. (1991). Myocardial L-carnitine deficiency in a family of dogs with DCM. JAVMA. PubMed — Boxer family; first canine carnitine-DCM link.
2. Keene BW, et al. (1991). L-carnitine supplementation in therapy of canine DCM. J Vet Intern Med. PubMed · DOI — Myopathic deficiency in 17-60% DCM dogs.
3. Sanderson SL (2006). Taurine and carnitine in canine cardiomyopathy. Vet Clin North Am Small Anim Pract. PubMed — 60% cardiac energy via beta-oxidation; safe to administer.
4. Smith et al. (2021). Diets associated with DCM in dogs: foodomics analysis. Sci Rep. PMC — 5-aminovaleric acid betaine inhibits carnitine transporter.
5. Weng et al. (2021). Efficacy of L-Carnitine for DCM: Meta-Analysis. Heart Fail Rev. PMC — Enhanced LCFA beta-oxidation and ATP production.

---

N34 — ⊘ SAMe (S-Adenosylmethionine) — NOT in LPL-01 Formulation — Comparative Genomic/Hepatic Geroscience Context

⊘ Formulation status note: SAMe is NOT included in Hollywood Elixir or Pet Gala. It is documented here because it is the direct substrate for DNA methyltransferases (the primary epigenetic aging mechanism), provides the most clinically established canine hepatoprotection pathway, and appears repeatedly in the Genomic Integrity (System 5) and Organ Reserve (System 6) sections of this framework. The methylation pathway in LPL-01 is addressed indirectly via B-vitamins (B12, B6, niacin — one-carbon cycle substrates); SAMe's direct DNMT substrate role is not replicated by any current formulation ingredient.

Biological role. S-adenosylmethionine is the primary biological methyl donor — the direct substrate for DNA methyltransferase (DNMT) enzymes that maintain epigenetic methylation patterns. SAMe also enters the transsulfuration pathway, generating cysteine for glutathione synthesis, and the polyamine pathway, producing decarboxylated SAMe as a spermidine precursor. In dogs, SAMe has established hepatoprotective applications: canine hepatocyte studies demonstrate NF-kB inhibition and reduced PGE2/IL-8/MCP-1 production. A prednisolone crossover RCT in 8 dogs monitored GSH as a safety biomarker, and SAMe has been used for acetaminophen toxicity rescue (loading dose 40 mg/kg). SAMe is preferred over NAC for oral GSH replacement in veterinary hepatoprotection.

Claims supported.

• Primary biological methyl donor — direct substrate for DNMT enzymes [B/C]
• GSH precursor via transsulfuration pathway [B/C]
• Canine hepatocyte study: NF-kB inhibition, reduced PGE2, IL-8, MCP-1
• Prednisolone crossover RCT (8 dogs): GSH monitoring
• Acetaminophen toxicity rescue: loading dose 40 mg/kg
• Preferred over NAC for oral GSH replacement in veterinary practice (PK1)

Where this fits.

• → Parent system: System 5 (N07), System 3 (N05), System 6 (N08)
• → BDC Subsystems: Genomic Stability (N14) — methylation/epigenetic substrates; Oxidative Defense (N10) — GSH synthesis
• → Cross-reference: B-Vitamins (N16) — one-carbon cycle; Glutathione/NAC (N17) — GSH synthesis pathway
• → Site architecture: /ingredients/same

Primary literature.

1. Au et al. (2012). SAMe and silybin hepatoprotective effects on canine hepatocytes in vitro. J Vet Intern Med. PubMed · DOI — NF-kB inhibition; reduced PGE2, IL-8, MCP-1.
2. Center et al. (2005). SAMe influence on prednisolone hepatic effects in dogs. Am J Vet Res. PubMed · DOI — 8 dogs, crossover; GSH monitoring.
3. Wallace et al. (2002). SAMe for acetaminophen toxicity in a dog. J Am Anim Hosp Assoc. PubMed · DOI — GSH rescue; loading dose 40 mg/kg.
4. Anstee et al. (2012). SAMe therapy in liver disease: review. J Hepatol. PubMed · DOI — Transmethylation, transsulfuration, aminopropylation pathways.
5. Center SA (2021). SAMe in veterinary hepatoprotection. Vet Clin North Am. — Preferred over NAC for oral GSH replacement.

---

N35 — Whey Protein / Leucine

Biological role. Whey protein is a leucine-rich protein source that stimulates muscle protein synthesis (MPS) via mTORC1 activation. Leucine directly activates mTORC1 through the Rag GTPase-Ragulator pathway, and this signaling is conserved across mammalian species. Canine sarcopenia — age-related muscle mass loss — is underdiagnosed and predicts early mortality. Histological studies reveal fibre atrophy, mitochondrial alterations, and upregulated autophagy in aging canine skeletal muscle. Labrador imaging studies demonstrate reduced epaxial muscle area correlating with declining lean body mass. Whey protein has rapid absorption kinetics and well-characterized amino acid absorption in dogs (PK1).

Claims supported.

• Leucine-rich protein stimulates mTOR-mediated muscle protein synthesis [B/PK1]
• Canine sarcopenia is underdiagnosed and predicts early mortality
• Histological: fibre atrophy, mitochondrial alterations, autophagy upregulation in aging canine muscle
• Labrador imaging: reduced epaxial muscle; lean body mass predicts lifespan
• Leucine-mTORC1 signaling conserved across mammalian species
• Synergistic MPS stimulation with resistance exercise (translational)

Where this fits.

• → Parent system: System 6 (N08) — musculoskeletal domain
• → Cross-reference: Tier-1 Levers (N01) — exercise as mTOR/AMPK modulator; L-Carnitine (N33) — metabolic support
• → Nutrient Sensing (N12): mTOR calibration — leucine directly activates mTORC1
• → Site architecture: /ingredients/whey-protein

Primary literature.

1. Freeman LM (2012). Cachexia and sarcopenia: emerging syndromes in dogs and cats. J Vet Intern Med. PubMed · DOI — Defines canine sarcopenia; predicts early mortality; nutritional strategies.
2. Pagano TB, et al. (2015). Age-related skeletal muscle atrophy and upregulation of autophagy in dogs. Vet J. PubMed · DOI — Histological: fibre atrophy, mitochondrial alterations, autophagy.
3. Freeman LM, et al. (2012). Assessment of methods of evaluating sarcopenia in old dogs. Am J Vet Res. PubMed · DOI — Labrador Retrievers; reduced epaxial muscle; LBM predicts lifespan.
4. Duan Y, et al. (2015). Leucine nutrition in animals and humans: mTOR signaling and beyond. Amino Acids. PubMed · DOI — Leucine activates mTORC1; conserved across mammals.
5. Ijaz S, et al. (2025). Leucine and Whey Protein in Sarcopenic Individuals. J Cachexia Sarcopenia Muscle. PubMed · DOI — Synergistic mTOR stimulation with resistance training.

---

Tier E — Scoring, Cross-Cutting Topics & Regulatory

---

N36 — BDC Scoring Methodology (Pathway Saturation, Evidence Ceilings, PK Modifiers, Composite Formula)

Biological role. Biological Defense Coverage (BDC) is a pathway-saturation scoring framework that quantifies the degree to which a nutritional intervention engages biochemically validated pathways within each of six subsystems. Each subsystem is scored 0–100 using five steps: pathway enumeration, engagement assessment, substrate depth evaluation, evidence-grade weighting (A=1.0×, B=0.85×, C=0.65×, D=0.50×), and PK confidence modifiers (PK1=1.0×, PK2=0.90×, PK3=0.75×). The composite BDC is the arithmetic mean of six subsystem scores. The scoring scale runs from 0–15 (minimal) through 76–100 (comprehensive). This methodology adapts GRADE principles from human clinical evidence grading to the specific challenges of veterinary nutraceutical evidence, where RCT depth is limited and species-specific PK data are often absent.

Claims supported.

• BDC quantifies nutritional engagement with biochemically validated pathways per subsystem
• Five-step scoring: pathway enumeration → engagement → substrate depth → evidence weighting → PK modifier
• Evidence ceiling weighting: A=1.0×, B=0.85×, C=0.65×, D=0.50×
• PK modifiers: PK1=1.0×, PK2=0.90×, PK3=0.75×
• Composite BDC = arithmetic mean of six subsystem scores
• Adapts GRADE principles for veterinary nutraceutical evidence context

Where this fits.

• → Applied to: all BDC Subsystem scores (N09–N14)
• → Evidence standards: Evidence Grading (N02) — grade definitions used here
• → Formulation: Formulation Crosswalk (N37) — multi-system architecture scored by BDC
• → Site architecture: /evidence/bdc-methodology

Primary literature.

1. Schünemann H, et al. (2013). GRADE Handbook for Grading Quality of Evidence. GRADE Working Group. — Gold-standard evidence-grading framework.
2. Vandeweerd JM, et al. (2012). Systematic review of nutraceutical efficacy in canine OA. J Vet Intern Med. PubMed — Only omega-3 well-supported; evidence quality low.
3. Block (2024). Evidence-based veterinary medicine — potential, practice, and pitfalls. Vet Rec. PMC — None of 212 vet RCT abstracts met CONSORT.
4. Sargeant JM, et al. (2020). Scoping Reviews, SRs, and Meta-Analysis in Veterinary Medicine. Front Vet Sci. PMC — Cochrane RoB adapted for animal studies.
5. Sargeant et al. (2022). Levels of Evidence and Risk of Bias in Primary Research. J Vet Intern Med. PMC — Roudebush veterinary nutrition evidence levels.

---

N37 — Formulation Crosswalk & Multi-System Architecture

Biological role. The six control systems of canine aging interact through shared molecular machinery, common upstream regulators, and bidirectional feedback loops — aging is a system-level phenomenon, not a single-target problem. Three documented cross-system cascades drive the rationale for multi-pathway formulation architecture: (1) metabolic dysregulation → inflammaging: chronic mTOR activation (from obesity, caloric excess, or declining AMPK activity) directly upregulates NF-κB inflammatory signaling and promotes the senescence-associated secretory phenotype; (2) inflammaging → oxidative stress: NF-κB-driven immune activation generates ROS as a metabolic byproduct in a self-amplifying loop that progressively depletes the antioxidant enzyme pool; (3) oxidative stress → senescence: persistent oxidative DNA damage is a primary trigger for p16INK4a/p21-mediated cellular senescence, whose SASP output drives further systemic inflammaging. AMPK sits at the crossroads of multiple hallmarks as a declining energy sensor, and mTOR functions as a central hub integrating nutrient signals with inflammatory and growth outputs.

LPL-01 multi-system coverage — formulation architecture summary:

Hollywood Elixir primary coverage: Systems 1 (NAD⁺/sirtuin), 2 (NF-κB/innate immune), 3 (multi-compartment antioxidant), 4 (indirect senescence upstream), 5 (genomic/epigenetic) Pet Gala primary coverage: Systems 2 (EPA/DHA resolvin — Grade [A] anchor), 3 (Zinc/SOD), 5 (Zinc DNA repair), 6 (EPA/DHA joint/cardiac/renal; L-Carnitine cardiac; Collagen/HA/MSM ECM) Combined system strongest coverage: Systems 2 (EPA/DHA + NF-κB stack), 3 (multi-pathway antioxidant), 6 (structural + metabolic + anti-inflammatory organ reserve) Combined system most limited coverage: System 4 (no canine senolytic data for any ingredient; upstream mechanisms only)

Key cross-system synergies between Hollywood Elixir and Pet Gala:

• System 2 synergy: HE's NF-κB/NLRP3 transcriptional modulation (quercetin, resveratrol) + innate immune calibration (beta-glucans, reishi) + PG's resolvin/protectin precursor supply (EPA/DHA) operate via complementary anti-inflammatory mechanisms — resolution (EPA/DHA) plus transcriptional suppression (polyphenols) plus immune training (beta-glucans)
• System 3 synergy: HE's direct antioxidant supply (glutathione, Vit C, Vit E, astaxanthin, CoQ10) + PG's enzymatic cofactor (Zinc/SOD) covers both non-enzymatic and enzymatic antioxidant arms simultaneously
• System 1 synergy: HE's NAD⁺/sirtuin axis (NR) + PG's fatty acid metabolic shuttle (L-Carnitine) address complementary metabolic regulation pathways (sirtuin-mediated deacetylation + beta-oxidation-driven AMPK)
• System 5 synergy: HE's B-vitamins (one-carbon cycle substrates) + NR (NAD⁺/SIRT6) + PG's Zinc (OGG1/PARP-1/p53 cofactor) provide three distinct genomic stability mechanisms
• System 6 synergy: PG's structural ECM stack (collagen/HA/MSM) + EPA/DHA (joint/cardiac/renal) + HE's CoQ10 (cardiac mitochondrial ETC) + B-vitamins (neuronal) addresses joint, cardiac, renal, and cognitive organ reserve from distinct mechanistic angles

Claims supported.

• Six control systems interact through shared molecular machinery and bidirectional feedback loops
• Metabolic dysregulation → inflammaging: chronic mTOR activation upregulates NF-κB [A/B]
• Inflammaging → oxidative stress: NF-κB-driven inflammation generates ROS in self-amplifying loop [C]
• Oxidative stress → senescence: persistent DNA damage triggers p16/p21 senescence; SASP drives further inflammation [C/D]
• Multi-pathway formulation reflects the cascade architecture of aging biology
• Hollywood Elixir covers NAD⁺/antioxidant/immune axes; Pet Gala covers structural/lipid/ECM/cardiac axes — together the system addresses all six control systems
• EPA/DHA (Pet Gala) is the Grade [A] evidence backbone across inflammaging, joint, cardiac, and renal domains
• NR (Hollywood Elixir) is the NAD⁺/sirtuin primary input — broadest theoretical multi-system reach; lowest direct canine evidence
• Beta Glucans + Reishi (Hollywood Elixir) provide innate immune calibration complementary to the EPA/DHA resolvin axis
• Combinatorial interventions show synergistic effects exceeding single-target approaches in aging models
• No ingredient in the current formulation has demonstrated lifespan extension in dogs; all claims are healthspan-support and pathway-saturation framing

Where this fits.

• → Integrates: all six control systems (N03–N08) and all six BDC subsystems (N09–N14)
• → Product-specific: Hollywood Elixir actives (N15–N25, N28, N35) and Pet Gala actives (N26, N30, N33)
• → Comparative context: ⊘ non-LPL-01 nodes (N27 Curcumin, N29 Fisetin/Spermidine, N30 UC-II/Glucosamine, N31 MCTs, N32 Taurine, N34 SAMe)
• → Scoring: BDC Scoring Methodology (N36) — multi-system scoring rationale
• → Boundary: Boundary Statements (N38) — what nutrition can and cannot do
• → Site architecture: /evidence/multi-system-architecture, /evidence/formulation-design

Primary literature.

1. Parkhitko et al. (2024). Combinatorial interventions in aging. Nat Aging. PMC — Multi-target combinations show synergistic effects exceeding single-target approaches.
2. Sanada et al. (2025). Targeting the hallmarks of aging: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. PubMed · DOI — Multi-targeted anti-aging therapies most promising; no single-target intervention addresses aging biology.
3. Papadopoli et al. (2019). mTOR as a central regulator of lifespan and aging. F1000Res. PMC — mTOR-NF-κB cross-talk; SASP via IL-1alpha; rationale for metabolic + inflammatory targeting.
4. López-Otín C, et al. (2013). The hallmarks of aging. Cell. PubMed — Foundational 9 hallmarks framework underpinning all six control system definitions.
5. López-Otín C, et al. (2023). Hallmarks of aging: An expanding universe. Cell. PubMed — Revised 12-hallmark framework incorporating dysbiosis, chronic inflammation, disabled macroautophagy.
6. Barbeau-Grégoire M, et al. (2022). 72-trial systematic review and meta-analysis of nutraceuticals in canine/feline OA. Animals. PMC — Omega-3 strongest single nutraceutical; validates EPA/DHA as formulation Grade [A] backbone for System 6.

---

N38 — Boundary Statements (Nutrition vs Veterinary Medicine)

Biological role. This node defines the regulatory and epistemic boundary between nutritional support and veterinary medical treatment. Nutritional interventions support normal biological structure and function — they do not diagnose, treat, cure, or prevent disease. FDA structure/function claim guidance restricts supplement claims to descriptions of how a nutrient affects normal body structure or function. The Dietary Supplement Health and Education Act (DSHEA) was not designed for animals; FDA-CVM applies more restrictive standards. NASC (National Animal Supplement Council) provides cGMP compliance and adverse event reporting standards. The primary domain for nutritional geroscience is normal aging when no disease is present — once clinical disease manifests, veterinary oversight is required.

Claims supported.

• Nutrition supports metabolic health; it does not treat diabetes, endocrine disease, or metabolic emergencies
• Nutrition supports inflammatory tone; it does not treat immune-mediated, infectious, or neoplastic disease
• Nutrition supports baseline antioxidant capacity; it does not treat acute oxidative emergencies
• Nutrition does not treat, prevent, or slow neoplastic disease
• Primary domain for nutritional geroscience: normal aging when no disease is present
• All statements describe support for normal biological structure and function; no disease claims

Where this fits.

• → Constrains: all ingredient nodes (N15–N35) — claim language restrictions
• → Evidence standards: Evidence Grading (N02) — what evidence can and cannot demonstrate
• → Cross-reference: Rapamycin (N39) — prescription drug vs nutraceutical distinction
• → Site architecture: /about/boundary-statements, /legal/disclaimer

Primary literature.

1. FDA (2023). Structure/Function Claims guidance. FDA.gov. — Cannot claim to diagnose, treat, cure, or prevent disease.
2. Perron et al. (2002). DSHEA and structure/function claims for animal feed. Regul Toxicol Pharmacol. PubMed — DSHEA not intended for animals; FDA-CVM more restrictive.
3. Dwyer JT, et al. (2019). Current regulatory guidelines for dietary supplements. Adv Nutr. PMC — Post-market regulation; no pre-approval.
4. Burdock Group (2022). Dietary Supplements for Pets — Are They Drugs? — Oral supplements must provide nutritive value; otherwise drugs.
5. NASC (2023). National Animal Supplement Council Quality Standards. — cGMP compliance, adverse event reporting.

---

N39 — Rapamycin & Pharmacologic Geroscience (TRIAD Trial, mTORC1 Inhibition)

Biological role. Rapamycin (sirolimus) is the most robust pharmacologic lifespan-extending intervention in mammalian models. It inhibits mTORC1 via FKBP12 binding, de-repressing autophagy through ULK1 complex activation. The first canine RCT (24 middle-aged companion dogs) demonstrated improved diastolic and systolic cardiac function with no side effects. The TRIAD trial — a multicenter, double-blind, placebo-controlled study of 580 dogs — is the first pharmacologic aging trial outside laboratory conditions, with lifespan as the primary endpoint. Rapamycin is a prescription drug requiring veterinary oversight; it is not a nutraceutical. Dose-dependent selectivity between mTORC1 (geroprotective) and mTORC2 (immunosuppressive) inhibition is a critical safety consideration, and breed-size pharmacokinetic scaling across the 2–80+ kg canine weight range is non-trivial.

Claims supported.

• Most robust pharmacologic lifespan-extending intervention in mammalian models (Harrison et al. 2009) [C]
• Canine RCT (24 dogs): improved cardiac diastolic and systolic function; no side effects [A]
• TRIAD: 580-dog multicenter RCT; first pharmacologic aging trial outside laboratory; lifespan primary endpoint [A — in progress]
• Prescription drug requiring veterinary oversight — not a nutraceutical
• Dose-dependent mTORC1 vs mTORC2 selectivity: geroprotective vs immunosuppressive
• Breed-size PK scaling across 2–80+ kg range is non-trivial

Where this fits.

• → Parent system: System 1 (N03) — mTOR calibration
• → BDC Subsystem: Nutrient Sensing (N12) — mTOR calibration and autophagy induction
• → Cross-reference: Dog Aging Project (N40) — TRIAD is a DAP initiative; Boundary Statements (N38) — prescription drug distinction
• → Site architecture: /evidence/rapamycin
• → ⚠️ Not a nutraceutical — prescription drug context only

Primary literature.

1. Urfer SR, et al. (2017). Short-term rapamycin treatment in 24 middle-aged companion dogs. GeroScience. PubMed — Improved cardiac diastolic and systolic function; no side effects.
2. Coleman KA, Creevy KE, et al. (2025). TRIAD study design and rationale. GeroScience. PubMed · DOI — Multicenter, double-blind, placebo-controlled; first pharmacologic aging trial outside laboratory.
3. Harrison DE, et al. (2009). Rapamycin fed late in life extends lifespan in mice. Nature. PubMed · DOI — Foundational; most robust pharmacologic lifespan extension.
4. Mannick et al. (2023). Targeting the biology of aging with mTOR inhibitors. Nat Aging. PMC — Autophagy de-repression; geroprotective dose windows.

---

N40 — Dog Aging Project & Canine Longevity Research

Biological role. The Dog Aging Project (DAP) is the largest longitudinal companion-animal study ever conducted, enrolling over 30,000 dogs with metabolome, microbiome, and epigenome data collection. It provides the population-scale epidemiological foundation for canine geroscience. Key DAP outputs include: canine epigenetic clocks validated across 93 breeds with human-dog dual-species clocks achieving R=0.97; the finding that once-daily feeding (n=24,238) is associated with lower cognitive dysfunction and disease odds; and the TRIAD rapamycin trial. The Kealy et al. (2002) caloric restriction study remains the only proven canine longevity intervention (+1.8 years). No nutritional supplement has demonstrated lifespan extension in controlled canine trials — the distinction between healthspan claims and lifespan extension must be maintained precisely.

Claims supported.

• DAP is the largest longitudinal companion-animal study (30,000+ dogs; metabolome, microbiome, epigenome)
• Canine epigenetic clocks validated across 93 breeds; dual human-dog clocks R=0.97 [B]
• Once-daily feeding (n=24,238): lower cognitive dysfunction and disease odds [B]
• No nutritional supplement has demonstrated lifespan extension in controlled canine trials
• Caloric restriction (Kealy et al. 2002) remains the only proven canine longevity intervention [A]
• Lifespan vs healthspan distinction must be maintained precisely

Where this fits.

• → Foundation for: all control systems (N03–N08) — population-level validation
• → Epigenetic clocks: System 5 (N07) — genomic integrity monitoring
• → TRIAD: Rapamycin (N39) — DAP initiative
• → Tier-1 Levers (N01): CR as only proven longevity intervention
• → Site architecture: /evidence/dog-aging-project

Primary literature.

1. Creevy KE, et al. (2022). An open science study of ageing in companion dogs. Nature. PubMed — 30,000+ dogs; metabolome, microbiome, epigenome; largest companion-animal aging study.
2. Horvath S, et al. (2022). DNA methylation clocks for dogs and humans. PNAS. PubMed — 93 breeds; human-dog dual-species clocks (R=0.97).
3. Bray EE, et al. (2022). Once-daily feeding and better health in companion dogs. GeroScience. PubMed · DOI — n=24,238; lower cognitive dysfunction and disease odds.
4. Kealy RD, et al. (2002). Diet restriction on life span in dogs. JAVMA. PubMed — 48 Labs; 25% CR → +1.8 yr median lifespan. Only proven intervention.
5. Lawler DF, et al. (2008). Diet restriction and ageing in the dog: 20 years. Br J Nutr. PubMed — Delayed OA, metabolic disease, neoplasia.

---

End of Structured Evidence Appendix — 40 nodes, 264 citations